{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "04ad8d34",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\Aidan\\miniconda3\\envs\\myenv\\lib\\site-packages\\tqdm\\auto.py:21: TqdmWarning: IProgress not found. Please update jupyter and ipywidgets. See https://ipywidgets.readthedocs.io/en/stable/user_install.html\n",
      "  from .autonotebook import tqdm as notebook_tqdm\n"
     ]
    }
   ],
   "source": [
    "import requests\n",
    "from bs4 import BeautifulSoup\n",
    "import yfinance as yf\n",
    "from datetime import datetime\n",
    "from datetime import timedelta\n",
    "import pandas as pd\n",
    "import json\n",
    "\n",
    "from functions import (get_sector, changes_from_press, get_content_header, \n",
    "                       get_df, normalise_to_index, save_data)\n",
    "\n",
    "past_last_date = False"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "2a0da762",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "http://lilly.mediaroom.com/2023-06-26-Lillys-phase-2-retatrutide-results-published-in-The-New-England-Journal-of-Medicine-show-the-investigational-molecule-achieved-up-to-17-5-mean-weight-reduction-at-24-weeks-in-adults-with-obesity-and-overweight\n",
      "http://lilly.mediaroom.com/2023-06-26-Lilly-Declares-Third-Quarter-2023-Dividend\n",
      "http://lilly.mediaroom.com/2023-06-24-Lillys-SURMOUNT-2-results-published-in-The-Lancet-show-tirzepatide-achieved-a-mean-weight-reduction-of-15-7-at-the-highest-dose-15-mg-in-adults-with-obesity-or-overweight-and-type-2-diabetes\n",
      "http://lilly.mediaroom.com/2023-06-23-Lillys-phase-2-results-published-in-the-New-England-Journal-of-Medicine-show-orforglipron,-a-once-daily-oral-nonpeptide-GLP-1-receptor-agonist,-achieved-up-to-14-7-mean-weight-reduction-at-36-weeks-in-adults-with-obesity-or-overweight\n",
      "http://lilly.mediaroom.com/2023-06-21-US-FDA-approves-Jardiance-R-empagliflozin-for-the-treatment-of-type-2-diabetes-in-children-10-years-and-older\n",
      "http://lilly.mediaroom.com/2023-06-20-Lilly-to-present-new-research-in-the-treatment-of-diabetes-and-obesity-at-the-American-Diabetes-Associations-R-83rd-Scientific-Sessions\n",
      "http://lilly.mediaroom.com/2023-06-20-Lilly-Teams-up-with-the-American-Diabetes-Association-and-Adam-Duvall-to-Launch-Tap-the-Cap\n",
      "http://lilly.mediaroom.com/2023-06-20-Lilly-to-Acquire-DICE-Therapeutics-to-Advance-Innovation-in-Immunology\n",
      "http://lilly.mediaroom.com/2023-06-16-First-Of-Its-Kind-Head-to-Head-Clinical-Trial-Reaffirms-the-Efficacy-of-Emgality-in-Episodic-Migraine-Prevention\n",
      "http://lilly.mediaroom.com/2023-06-02-Lilly-Highlights-Verzenio-R-abemaciclib-and-Jaypirca-TM-pirtobrutinib-Data-at-2023-ASCO-R-Annual-Meeting\n",
      "http://lilly.mediaroom.com/2023-05-30-Lilly-to-Participate-in-Goldman-Sachs-Global-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2023-05-22-Lilly-ESG-Report-Highlights-Progress-Towards-Sustainability-Goals\n",
      "http://lilly.mediaroom.com/2023-05-18-Lillys-peresolimab-Phase-2a-rheumatoid-arthritis-trial-published-in-The-New-England-Journal-of-Medicine\n",
      "http://lilly.mediaroom.com/2023-05-11-Loxo-Lilly-Announces-Details-of-Presentations-at-2023-European-Hematology-Association-EHA-Annual-Meeting\n",
      "http://lilly.mediaroom.com/2023-05-09-Lillys-Social-Impact-Venture-Capital-Portfolio-Poised-to-Grow-to-300-Million-with-New-50-Million-Allocation\n",
      "http://lilly.mediaroom.com/2023-05-09-Lilly-Discloses-First-in-Class,-Interim-Phase-2-Data-in-Pediatric-Patients-and-New-Analysis-from-Phase-3-Program-in-Adult-Patients-for-Mirikizumab-in-Ulcerative-Colitis\n",
      "http://lilly.mediaroom.com/2023-05-03-Lilly-to-Participate-in-Bank-of-America-Securities-2023-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2023-05-03-Lillys-Donanemab-Significantly-Slowed-Cognitive-and-Functional-Decline-in-Phase-3-Study-of-Early-Alzheimers-Disease\n",
      "http://lilly.mediaroom.com/2023-05-02-Lilly-Provides-500,000-in-Grants-to-Support-Equitable-Access-to-Education-for-Dreamers-in-Indiana\n",
      "http://lilly.mediaroom.com/2023-05-01-Lilly-Declares-Second-Quarter-2023-Dividend\n",
      "http://lilly.mediaroom.com/2023-05-01-Up-to-73-of-Atopic-Dermatitis-Patients-Taking-Lillys-Lebrikizumab-Had-Improved-or-Cleared-Skin-on-Face-or-Hands-in-New-Analysis\n",
      "http://lilly.mediaroom.com/2023-04-27-Lilly-Reports-First-Quarter-2023-Financial-Results,-Highlights-Continued-Core-Business-Growth-and-Pipeline-Momentum\n",
      "http://lilly.mediaroom.com/2023-04-27-Lillys-tirzepatide-achieved-up-to-15-7-weight-loss-in-adults-with-obesity-or-overweight-and-type-2-diabetes-in-SURMOUNT-2\n",
      "http://lilly.mediaroom.com/2023-04-24-Lilly-to-Divest-BAQSIMI-to-Amphastar\n",
      "http://lilly.mediaroom.com/2023-04-17-Lilly-to-Make-Record-Breaking-Investment-in-Indiana-Manufacturing-Facilities\n",
      "http://lilly.mediaroom.com/2023-04-13-U-S-Food-and-Drug-Administration-Issues-Complete-Response-Letter-for-Mirikizumab\n",
      "http://lilly.mediaroom.com/2023-04-13-Lilly-Confirms-Date-and-Conference-Call-for-First-Quarter-2023-Financial-Results-Announcement\n",
      "http://lilly.mediaroom.com/2023-03-14-Lilly-Announces-Details-of-Presentations-at-2023-American-Association-for-Cancer-Research-AACR-Annual-Meeting\n",
      "http://lilly.mediaroom.com/2023-03-08-Lilly-Provides-Update-on-A4-Study-of-Solanezumab-for-Preclinical-Alzheimers-Disease\n",
      "http://lilly.mediaroom.com/2023-03-08-US-FDA-accepts-supplemental-New-Drug-Application-for-Jardiance-R-for-children-10-years-and-older-with-type-2-diabetes\n",
      "http://lilly.mediaroom.com/2023-03-06-Intensive-education-at-clinics-about-multidisciplinary-care-improved-likelihood-that-adults-with-type-2-diabetes-and-cardiovascular-disease-were-receiving-guideline-directed-medicines,-according-to-real-world-study\n",
      "http://lilly.mediaroom.com/2023-03-03-U-S-FDA-Broadens-Indication-for-Verzenio-R-abemaciclib-in-HR-,-HER2-,-Node-Positive,-High-Risk-Early-Breast-Cancer\n",
      "http://lilly.mediaroom.com/2023-03-01-Lilly-Cuts-Insulin-Prices-by-70-and-Caps-Patient-Insulin-Out-of-Pocket-Costs-at-35-Per-Month\n",
      "http://lilly.mediaroom.com/2023-02-21-Lilly-to-Participate-in-Cowens-43rd-Annual-Health-Care-Conference\n",
      "http://lilly.mediaroom.com/2023-02-13-Lilly-and-IABL-Collaborate-to-Ensure-Patient-Access-to-High-Quality-Affordable-Insulin-in-Bangladesh\n",
      "http://lilly.mediaroom.com/2023-02-07-Lilly-to-Participate-in-SVB-Securities-Global-Biopharma-Conference\n",
      "http://lilly.mediaroom.com/2023-02-03-Lilly-to-Participate-in-Guggenheim-Oncology-Conference\n",
      "http://lilly.mediaroom.com/2023-02-02-Lilly-Reports-Fourth-Quarter-2022-Financial-Results,-Core-Business-Growth-and-Pipeline-Advancements-Support-Strong-Long-Term-Outlook\n",
      "http://lilly.mediaroom.com/2023-01-27-U-S-FDA-Approves-Jaypirca-TM-pirtobrutinib-,-the-First-and-Only-Non-Covalent-Reversible-BTK-Inhibitor,-for-Adult-Patients-with-Relapsed-or-Refractory-Mantle-Cell-Lymphoma-After-at-Least-Two-Lines-of-Systemic-Therapy,-Including-a-BTK-Inhibitor\n",
      "http://lilly.mediaroom.com/2023-01-26-Lilly-Supports-Direct-Reliefs-Efforts-to-Expand-Access-to-Medicines-by-Improving-Cold-Chain-Capacity\n",
      "http://lilly.mediaroom.com/2023-01-24-Lilly-Plans-to-Invest-Additional-450-million-at-Manufacturing-Site-in-Research-Triangle-Park\n",
      "http://lilly.mediaroom.com/2023-01-20-US-FDA-accepts-supplemental-New-Drug-Application-for-Jardiance-R-for-adults-with-chronic-kidney-disease\n",
      "http://lilly.mediaroom.com/2023-01-19-U-S-Food-and-Drug-Administration-Issues-Complete-Response-Letter-for-Accelerated-Approval-of-Donanemab\n",
      "http://lilly.mediaroom.com/2023-01-19-Lilly-Confirms-Date-and-Conference-Call-for-Fourth-Quarter-2022-Financial-Results-Announcement\n",
      "http://lilly.mediaroom.com/2023-01-04-Lilly-to-Participate-in-the-J-P-Morgan-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2022-12-22-Lilly-and-ProQR-to-Expand-RNA-Editing-Collaboration\n",
      "http://lilly.mediaroom.com/2022-12-14-Lilly-and-EVA-Pharma-Announce-Collaboration-to-Enhance-Sustainable-Access-to-Affordable-Insulin-in-Africa\n",
      "http://lilly.mediaroom.com/2022-12-13-Lilly-Announces-2023-Financial-Guidance,-Plans-to-Launch-up-to-Four-New-Medicines\n",
      "http://lilly.mediaroom.com/2022-12-12-Loxo-Lilly-Presents-Updated-Pirtobrutinib-Data-from-the-Phase-1-2-BRUIN-Clinical-Trial-at-the-2022-American-Society-of-Hematology-Annual-Meeting\n",
      "http://lilly.mediaroom.com/2022-12-12-Lilly-Announces-15-Dividend-Increase,-First-Quarter-2023-Dividend\n",
      "http://lilly.mediaroom.com/2022-12-07-Phase-III-trial-demonstrated-Jardiance-R-is-the-first-SGLT2-inhibitor-to-show-statistically-significant-reduction-in-blood-sugar-levels-in-children-and-adolescents-with-type-2-diabetes\n",
      "http://lilly.mediaroom.com/2022-12-06-Lilly-Announces-Updated-Data-from-the-Verzenio-R-abemaciclib-Phase-3-monarchE-Trial-Presented-at-SABCS-and-Simultaneously-Published-in-The-Lancet-Oncology\n",
      "http://lilly.mediaroom.com/2022-12-01-Lilly-Completes-Acquisition-of-Akouos-Expanding-Efforts-to-Help-People-with-Genetic-Diseases\n",
      "http://lilly.mediaroom.com/2022-11-30-Lilly-Shares-Positive-Donanemab-Data-in-First-Active-Comparator-Study-in-Early-Symptomatic-Alzheimers-Disease\n",
      "http://lilly.mediaroom.com/2022-11-30-Lilly-and-Akouos-Announce-Expiration-of-Akouos-Tender-Offer\n",
      "http://lilly.mediaroom.com/2022-11-29-Lilly-Confirms-Date-and-Conference-Call-for-2023-Financial-Guidance-Announcement\n",
      "http://lilly.mediaroom.com/2022-11-21-Lilly-Announces-Details-of-Presentations-at-2022-San-Antonio-Breast-Cancer-Symposium\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "http://lilly.mediaroom.com/2022-11-16-Lilly-to-Participate-in-Evercore-ISI-HealthCONx-Conference\n",
      "http://lilly.mediaroom.com/2022-11-07-Lilly-to-begin-rollout-of-Tempo-R-Personalized-Diabetes-Management-Platform\n",
      "http://lilly.mediaroom.com/2022-11-04-Landmark-EMPA-KIDNEY-trial-showed-significant-benefit-of-Jardiance-R-in-reducing-kidney-disease-progression-or-cardiovascular-death-by-28-vs-placebo-in-people-with-chronic-kidney-disease\n",
      "http://lilly.mediaroom.com/2022-11-03-Loxo-Lilly-Announces-Details-of-Presentations-at-the-2022-American-Society-of-Hematology-Annual-Meeting\n",
      "http://lilly.mediaroom.com/2022-11-01-Lilly-Reports-Solid-Third-Quarter-2022-Financial-Results-and-Continued-Pipeline-Progress\n",
      "http://lilly.mediaroom.com/2022-10-27-Lilly-commits-92-5-million-to-Purdue-to-establish-an-innovative-pharmaceutical-manufacturing-scholarship-program-and-to-extend-research-collaboration\n",
      "http://lilly.mediaroom.com/2022-10-19-Lilly-Confirms-Date-and-Conference-Call-for-Third-Quarter-2022-Financial-Results-Announcement\n",
      "http://lilly.mediaroom.com/2022-10-18-Lilly-to-Acquire-Akouos-to-Discover-and-Develop-Treatments-for-Hearing-Loss\n",
      "http://lilly.mediaroom.com/2022-10-17-Lilly-Declares-Fourth-Quarter-2022-Dividend\n",
      "http://lilly.mediaroom.com/2022-10-06-Lilly-receives-U-S-FDA-Fast-Track-designation-for-tirzepatide-for-the-treatment-of-adults-with-obesity,-or-overweight-with-weight-related-comorbidities\n",
      "http://lilly.mediaroom.com/2022-09-21-FDA-Approves-Lillys-Retevmo-R-selpercatinib-,-the-First-and-Only-RET-Inhibitor-for-Adults-with-Advanced-or-Metastatic-Solid-Tumors-with-a-RET-Gene-Fusion,-Regardless-of-Type\n",
      "http://lilly.mediaroom.com/2022-09-08-Lebrikizumab-Dosed-Every-Four-Weeks-Maintained-Durable-Skin-Clearance-in-Lillys-Phase-3-Monotherapy-Atopic-Dermatitis-Trials\n",
      "http://lilly.mediaroom.com/2022-09-07-Lilly-Announces-Details-of-Presentations-at-ESMO-Congress-2022\n",
      "http://lilly.mediaroom.com/2022-08-31-Lilly-to-Participate-in-Morgan-Stanley-20th-Annual-Global-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2022-08-25-Lilly-to-Participate-in-Citis-17th-Annual-BioPharma-Conference\n",
      "http://lilly.mediaroom.com/2022-08-11-Lilly-Announces-Leadership-Transition-in-Human-Resources-and-New-Chief-Commercial-Officer-for-Loxo-Lilly\n",
      "http://lilly.mediaroom.com/2022-08-08-Lillys-Taltz-R-ixekizumab-Now-Available-in-New,-Citrate-Free-Formulation-to-Reduce-Injection-Site-Pain-for-Improved-Patient-Experience\n",
      "http://lilly.mediaroom.com/2022-08-04-Lilly-Updates-Conference-Call-Start-Time-for-Second-Quarter-2022-Financial-Results\n",
      "http://lilly.mediaroom.com/2022-08-04-Lilly-Reports-Second-Quarter-Financial-Results,-Highlights-Momentum-of-New-Medicines-and-Pipeline-Advancements\n",
      "http://lilly.mediaroom.com/2022-07-21-Lilly-Confirms-Date-and-Conference-Call-for-Second-Quarter-2022-Financial-Results-Announcement\n",
      "http://lilly.mediaroom.com/2022-06-29-Lilly-will-supply-an-additional-150,000-doses-of-bebtelovimab-to-U-S-government-in-ongoing-effort-to-provide-COVID-19-treatment-options\n",
      "http://lilly.mediaroom.com/2022-06-27-Lilly-Declares-Third-Quarter-2022-Dividend\n",
      "http://lilly.mediaroom.com/2022-06-13-FDA-Approves-Lilly-and-Incytes-OLUMIANT-R-baricitinib-As-First-and-Only-Systemic-Medicine-for-Adults-with-Severe-Alopecia-Areata\n",
      "http://lilly.mediaroom.com/2022-06-07-Eight-out-of-Ten-Patients-Maintained-Skin-Clearance-at-One-Year-in-Lillys-Lebrikizumab-Atopic-Dermatitis-Monotherapy-Trials\n",
      "http://lilly.mediaroom.com/2022-06-06-New-analyses-of-Mounjaro-TM-tirzepatide-injection-for-the-treatment-of-adults-with-type-2-diabetes-presented-at-the-American-Diabetes-Associations-R-82nd-Scientific-Sessions-R\n",
      "http://lilly.mediaroom.com/2022-06-05-Jardiance-R-decreased-relative-risk-of-hospitalization-for-heart-failure-by-50-versus-DPP-4-inhibitors-and-by-30-versus-GLP-1-receptor-agonists-in-adults-with-type-2-diabetes-in-real-world-evidence-study\n",
      "http://lilly.mediaroom.com/2022-06-04-Lillys-AWARD-PEDS-trial-investigating-use-of-Trulicity-R-dulaglutide-in-youth-and-adolescents-with-type-2-diabetes-showed-superiority-in-A1C-reduction-vs-placebo\n",
      "http://lilly.mediaroom.com/2022-06-04-Lillys-SURMOUNT-1-results-published-in-The-New-England-Journal-of-Medicine-show-tirzepatide-achieved-between-16-0-and-22-5-weight-loss-in-adults-with-obesity-or-overweight\n",
      "http://lilly.mediaroom.com/2022-06-03-Lilly-to-Participate-in-Goldman-Sachs-Global-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2022-05-26-Lilly-Announces-Details-of-Presentations-at-2022-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting\n",
      "http://lilly.mediaroom.com/2022-05-25-Lilly-plans-to-invest-2-1-billion-in-new-manufacturing-sites-in-Indiana\n",
      "http://lilly.mediaroom.com/2022-05-24-Fifty-Percent-of-Patients-with-Ulcerative-Colitis-Treated-with-Mirikizumab-Achieved-Clinical-Remission-at-One-Year-in-Lillys-Pivotal-Phase-3-Study\n",
      "http://lilly.mediaroom.com/2022-05-23-Lilly-Announces-Webcast-to-Provide-Diabetes-and-Obesity-Portfolio-Update-at-ADA\n",
      "http://lilly.mediaroom.com/2022-05-20-CHMP-Recommends-Approval-of-Lilly-and-Incytes-OLUMIANT-R-baricitinib-as-the-First-and-Only-Centrally-Authorized-Treatment-for-Adults-with-Severe-Alopecia-Areata-AA\n",
      "http://lilly.mediaroom.com/2022-05-16-Lilly-to-Participate-in-UBS-Global-Healthcare-Conference-2022\n",
      "http://lilly.mediaroom.com/2022-05-13-FDA-approves-Lillys-Mounjaro-TM-tirzepatide-injection,-the-first-and-only-GIP-and-GLP-1-receptor-agonist-for-the-treatment-of-adults-with-type-2-diabetes\n",
      "http://lilly.mediaroom.com/2022-05-11-FDA-Approves-Lilly-and-Incytes-OLUMIANT-R-baricitinib-for-the-Treatment-of-Certain-Hospitalized-Patients-with-COVID-19\n",
      "http://lilly.mediaroom.com/2022-05-06-Mary-Lynne-Hedley-Elected-to-Lilly-Board-of-Directors\n",
      "http://lilly.mediaroom.com/2022-05-03-Lilly-to-Participate-in-Bank-of-America-Securities-2022-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2022-05-02-Lilly-Declares-Second-Quarter-2022-Dividend\n",
      "http://lilly.mediaroom.com/2022-04-28-Solid-First-Quarter-Financial-Results-Reflect-Lillys-Continued-Momentum-into-2022\n",
      "http://lilly.mediaroom.com/2022-04-28-Lillys-tirzepatide-delivered-up-to-22-5-weight-loss-in-adults-with-obesity-or-overweight-in-SURMOUNT-1\n",
      "http://lilly.mediaroom.com/2022-04-20-Tackling-Health-Disparities-and-Inequities-for-Women-with-Heart-Failure-New-Program-Encourages-Black-and-Latina-Women-to-Demand-More-From-Their-Care\n",
      "http://lilly.mediaroom.com/2022-04-19-Lilly-Confirms-Date-and-Conference-Call-for-First-Quarter-2022-Financial-Results-Announcement\n",
      "http://lilly.mediaroom.com/2022-04-11-Lillys-Lebrikizumab-Combined-with-Topical-Corticosteroids-Showed-Significant-Improvements-in-Disease-Severity-for-Atopic-Dermatitis\n",
      "http://lilly.mediaroom.com/2022-04-01-Lilly-Presents-Updated-Data-on-Retevmo-R-selpercatinib-in-Advanced-RET-Fusion-Positive-Non-Small-Cell-Lung-Cancer-NSCLC-at-the-2022-European-Lung-Cancer-Congress\n",
      "http://lilly.mediaroom.com/2022-03-26-Nearly-40-of-Adults-with-Alopecia-Areata-Taking-OLUMIANT-R-4-mg-Saw-at-Least-80-Scalp-Hair-Coverage-at-52-Weeks-in-Lillys-Pivotal-Phase-3-Studies\n",
      "http://lilly.mediaroom.com/2022-03-26-Majority-of-Patients-Treated-with-Lebrikizumab-Achieved-Skin-Clearance-in-Lillys-Pivotal-Phase-3-Atopic-Dermatitis-Studies\n",
      "http://lilly.mediaroom.com/2022-03-24-Lilly-Announces-Complete-Response-Letter-for-Sintilimab-in-Combination-with-Pemetrexed-and-Platinum-Chemotherapy-for-the-First-Line-Treatment-of-People-with-Nonsquamous-Non-Small-Cell-Lung-Cancer\n",
      "http://lilly.mediaroom.com/2022-03-16-Jardiance-R-phase-III-EMPA-KIDNEY-trial-will-stop-early-due-to-clear-positive-efficacy-in-people-with-chronic-kidney-disease\n",
      "http://lilly.mediaroom.com/2022-03-08-Lilly-Announces-Details-of-Presentations-at-2022-American-Association-for-Cancer-Research-AACR\n",
      "http://lilly.mediaroom.com/2022-03-03-Lilly-to-Participate-in-Barclays-Global-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2022-03-01-Jardiance-R-provided-a-significant-clinical-benefit-in-adults-stabilized-in-hospital-following-acute-heart-failure-in-EMPULSE-phase-III-trial\n",
      "http://lilly.mediaroom.com/2022-02-28-Lilly-to-Participate-in-Cowen-Health-Care-Conference\n",
      "http://lilly.mediaroom.com/2022-02-24-US-FDA-approves-Jardiance-R-empagliflozin-to-treat-adults-with-heart-failure-regardless-of-left-ventricular-ejection-fraction\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "http://lilly.mediaroom.com/2022-02-22-Lilly-Announces-the-Institute-for-Genetic-Medicine-and-700-Million-investment-in-Boston-Seaport-Site\n",
      "http://lilly.mediaroom.com/2022-02-18-Nearly-Two-Thirds-of-Patients-Respond-to-Mirikizumab-Treatment-at-12-Weeks-in-Lillys-First-in-Class-Ulcerative-Colitis-Phase-3-LUCENT-1-Study\n",
      "http://lilly.mediaroom.com/2022-02-16-Lilly-and-Breast-Cancer-Advocacy-Organizations-Collaborate-to-Drive-Awareness-of-the-Complexities-of-Early-Breast-Cancer-and-the-Risk-of-Recurrence\n",
      "http://lilly.mediaroom.com/2022-02-11-Lillys-bebtelovimab-receives-Emergency-Use-Authorization-for-the-treatment-of-mild-to-moderate-COVID-19\n",
      "http://lilly.mediaroom.com/2022-02-10-Lilly-will-supply-up-to-600,000-doses-of-bebtelovimab-to-U-S-government-in-ongoing-effort-to-provide-COVID-19-treatment-options\n",
      "http://lilly.mediaroom.com/2022-02-10-Cynthia-Cardona-Elected-as-President-of-the-Lilly-Foundation\n",
      "http://lilly.mediaroom.com/2022-02-03-Lilly-Reports-Solid-Fourth-Quarter-and-Full-Year-2021-Financial-Results,-Recent-Late-Stage-Pipeline-Successes-Set-Up-Next-Wave-of-Innovative-Medicines-for-Patients\n",
      "http://lilly.mediaroom.com/2022-02-02-UNICEF-and-Lilly-Collaborate-to-Help-Improve-Health-Outcomes-for-10-Million-Children-and-Adolescents\n",
      "http://lilly.mediaroom.com/2022-02-01-Lilly-to-Participate-in-Guggenheim-Oncology-Conference\n",
      "http://lilly.mediaroom.com/2022-01-28-Lilly-announces-1-billion-investment-in-new-manufacturing-facility-in-North-Carolina\n",
      "http://lilly.mediaroom.com/2022-01-28-Updates-on-OLUMIANT-R-baricitinib-Phase-3-lupus-program-and-FDA-review-for-atopic-dermatitis\n",
      "http://lilly.mediaroom.com/2022-01-20-Lilly-Confirms-Date-and-Conference-Call-for-Fourth-Quarter-and-Full-Year-2021-Financial-Results-Announcement\n",
      "http://lilly.mediaroom.com/2022-01-06-Lilly-to-Participate-in-the-J-P-Morgan-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2022-01-06-Lilly-and-Entos-Pharmaceuticals-Enter-into-Research-and-Collaboration-Agreement-to-Support-the-Development-of-Innovative-Therapies-in-Multiple-Neurologic-Indications\n",
      "http://lilly.mediaroom.com/2021-12-21-Lillys-lebrikizumab-demonstrated-significant-skin-improvement-and-itch-relief-when-combined-with-topical-corticosteroids-in-people-with-atopic-dermatitis-in-third-Phase-3-study\n",
      "http://lilly.mediaroom.com/2021-12-15-Lilly-Highlights-Innovation-based-Growth-Strategy-and-Pipeline-Developments-Announces-2022-Financial-Guidance-at-Investment-Community-Meeting\n",
      "http://lilly.mediaroom.com/2021-12-14-Mirikizumab-Demonstrates-Superiority-over-Placebo-in-Phase-3-Maintenance-Study-in-Ulcerative-Colitis,-Supporting-Regulatory-Submissions-in-2022\n",
      "http://lilly.mediaroom.com/2021-12-13-Lilly-Announces-15-Percent-Dividend-Increase,-First-Quarter-2022-Dividend\n",
      "http://lilly.mediaroom.com/2021-12-13-Lilly-and-Foghorn-Announce-Strategic-Collaboration-for-Novel-Oncology-Targets-Using-Foghorns-Proprietary-Gene-Traffic-Control-R-Platform\n",
      "http://lilly.mediaroom.com/2021-12-12-Loxo-Oncology-at-Lilly-Announces-Updated-Data-from-the-Phase-1-2-BRUIN-Clinical-Trial-for-Pirtobrutinib-at-the-American-Society-of-Hematology-Annual-Meeting\n",
      "http://lilly.mediaroom.com/2021-12-10-Lilly-and-Regor-Therapeutics-Group-Enter-into-Strategic-Collaboration-to-Discover-and-Develop-Novel-Therapies-for-Metabolic-Disorders\n",
      "http://lilly.mediaroom.com/2021-12-09-New-Lilly-Study-Reveals-Underappreciation-of-Bowel-Urgency-as-a-Symptom-of-Ulcerative-Colitis-and-Highlights-Communication-Gap-Between-Healthcare-Providers-and-Patients\n",
      "http://lilly.mediaroom.com/2021-12-03-Lillys-bamlanivimab-with-etesevimab-authorized-as-the-first-and-only-neutralizing-antibody-therapy-for-emergency-use-in-COVID-19-patients-under-the-age-of-12\n",
      "http://lilly.mediaroom.com/2021-12-01-Lilly-to-Announce-Initial-2022-Financial-Guidance-Provide-R-D-Overview-at-Investment-Community-Meeting\n",
      "http://lilly.mediaroom.com/2021-11-18-Emgality-R-Versus-Nurtec-R-ODT-Head-to-Head-Migraine-Preventive-Treatment-Study-Now-Enrolling-Patients\n",
      "http://lilly.mediaroom.com/2021-11-17-Lilly-to-Participate-in-Fourth-Annual-Evercore-ISI-HealthCONx-Conference\n",
      "http://lilly.mediaroom.com/2021-11-11-US-FDA-accepts-supplemental-New-Drug-Application-and-grants-Priority-Review-for-Jardiance-R-for-adults-with-heart-failure-independent-of-left-ventricular-ejection-fraction\n",
      "http://lilly.mediaroom.com/2021-11-11-Lilly-announces-winners-of-inaugural-Leonard-Award,-a-global-program-celebrating-100-years-of-innovation-in-diabetes-care\n",
      "http://lilly.mediaroom.com/2021-11-09-Lilly-to-Participate-in-Wolfe-Research-Virtual-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2021-11-09-OLUMIANT-R-Long-Term-Safety-Profile-Established-Up-to-9-3-Years-in-Integrated-Analysis-of-More-Than-3,700-Patients-with-Rheumatoid-Arthritis\n",
      "http://lilly.mediaroom.com/2021-11-05-Jardiance-R-shows-consistent-cardio-renal-benefits-in-adults-with-heart-failure-with-left-ventricular-ejection-fraction-over-40-regardless-of-chronic-kidney-disease-status\n",
      "http://lilly.mediaroom.com/2021-11-04-Loxo-Oncology-at-Lilly-Announces-Details-of-Presentations-at-the-2021-American-Society-of-Hematology-ASH-Annual-Meeting\n",
      "http://lilly.mediaroom.com/2021-11-02-Lilly-to-supply-614,000-additional-doses-of-bamlanivimab-and-etesevimab-to-the-U-S-Government-for-the-treatment-or-post-exposure-prevention-of-COVID-19\n",
      "http://lilly.mediaroom.com/2021-11-01-Lilly-to-Participate-in-Bernsteins-Second-Annual-Operational-Decisions-Conference\n",
      "http://lilly.mediaroom.com/2021-10-28-Additional-Verzenio-R-abemaciclib-Phase-3-monarchE-Trial-Data-Published-in-the-Annals-of-Oncology\n",
      "http://lilly.mediaroom.com/2021-10-26-Lilly-Reports-Robust-Third-Quarter-2021-Financial-Results-as-Pipeline-Success-Strengthens-Future-Growth-Potential\n",
      "http://lilly.mediaroom.com/2021-10-19-Tirzepatide-results-published-in-The-Lancet-show-superior-A1C-and-body-weight-reductions-compared-to-insulin-glargine-in-adults-with-type-2-diabetes-with-increased-cardiovascular-risk\n",
      "http://lilly.mediaroom.com/2021-10-18-Lilly-Declares-Fourth-Quarter-2021-Dividend\n",
      "http://lilly.mediaroom.com/2021-10-14-Lilly-Announces-Updated-Verzenio-R-abemaciclib-Phase-3-monarchE-Trial-Data-Presented-at-ESMO-Virtual-Plenary-and-Simultaneously-Published-in-the-Annals-of-Oncology\n",
      "http://lilly.mediaroom.com/2021-10-13-FDA-Approves-Verzenio-R-abemaciclib-as-the-First-and-Only-CDK4-6-Inhibitor-for-Certain-People-with-HR-HER2-High-Risk-Early-Breast-Cancer\n",
      "http://lilly.mediaroom.com/2021-10-12-Lilly-Confirms-Date-and-Conference-Call-for-Third-Quarter-2021-Financial-Results-Announcement\n",
      "http://lilly.mediaroom.com/2021-10-07-Loxo-Oncology-at-Lilly-Announces-Details-of-Presentations-at-2021-AACR-NCI-EORTC-Virtual-International-Conference-on-Molecular-Targets-and-Cancer-Therapeutics\n",
      "http://lilly.mediaroom.com/2021-10-04-Ready-for-the-Challenge-Boehringer-Ingelheim-and-Eli-Lilly-and-Company-Launch-First-Ever-Online-Game-on-Cardio-Renal-Metabolic-Conditions-for-Healthcare-Professionals\n",
      "http://lilly.mediaroom.com/2021-10-01-At-Week-104,-75-of-Patients-with-Ulcerative-Colitis-Taking-Mirikizumab-Maintained-Symptomatic-Remission-in-Phase-2-Study\n",
      "http://lilly.mediaroom.com/2021-09-30-OLUMIANT-R-Significantly-Improved-Hair-Regrowth-to-At-Least-80-Scalp-Coverage-as-Early-as-24-Weeks-Across-First-Completed-Phase-3-Studies-for-Alopecia-Areata\n",
      "http://lilly.mediaroom.com/2021-09-30-Lillys-tirzepatide-led-to-greater-improvements-in-liver-fat-content-compared-to-insulin-degludec-in-adults-with-type-2-diabetes-in-SURPASS-3-MRI-sub-study\n",
      "http://lilly.mediaroom.com/2021-09-30-Lillys-tirzepatide-led-to-greater-time-in-range-compared-to-insulin-degludec-in-adults-with-type-2-diabetes-in-SURPASS-3-CGM-sub-study\n",
      "http://lilly.mediaroom.com/2021-09-29-Lilly-and-Susan-G-Komen-R-Partner-to-Address-Disparities-in-Breast-Cancer-Outcomes-Experienced-By-Black-Women\n",
      "http://lilly.mediaroom.com/2021-09-28-FDA-Expands-Lillys-ERBITUX-R-cetuximab-Label-with-Combination-of-BRAFTOVI-R-encorafenib-for-the-Treatment-of-BRAF-V600E-Mutation-Positive-Metastatic-Colorectal-Cancer-CRC-after-Prior-Therapy\n",
      "http://lilly.mediaroom.com/2021-09-28-Lilly-again-reduces-list-price-of-Insulin-Lispro-Injection-as-latest-change-to-affordability-options\n",
      "http://lilly.mediaroom.com/2021-09-27-New-Data-from-Verzenio-R-abemaciclib-monarchE-Study-to-Be-Featured-in-ESMO-Virtual-Plenary\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "http://lilly.mediaroom.com/2021-09-24-Eli-Lilly-and-Company-Issues-Voluntary-Nationwide-Recall-of-One-Lot-of-GLUCAGON-R-Emergency-Kit-Due-to-Loss-of-Potency\n",
      "http://lilly.mediaroom.com/2021-09-21-Lilly-Announces-the-Pricing-Terms-of-Its-Cash-Tender-Offer-for-Up-to-1-5-Billion-Combined-Aggregate-Principal-Amount-of-Its-Outstanding-Debt-Securities\n",
      "http://lilly.mediaroom.com/2021-09-21-Lilly-announces-procurement-agreement-with-European-Commission-to-supply-bamlanivimab-and-etesevimab-together-for-the-treatment-of-confirmed-COVID-19\n",
      "http://lilly.mediaroom.com/2021-09-21-Lilly-Announces-the-Early-Tender-Results-of-Its-Pending-Cash-Tender-Offer-for-Up-to-1-5-Billion-Combined-Aggregate-Principal-Amount-of-Its-Outstanding-Debt-Securities-and-Removal-of-the-Note-Caps-for-Its-3-950-Notes-due-2049-and-Its-4-150-Notes\n",
      "http://lilly.mediaroom.com/2021-09-16-Emergency-Use-Authorization-for-Lillys-bamlanivimab-and-etesevimab-administered-together-expanded-to-include-post-exposure-prophylaxis-for-COVID-19\n",
      "http://lilly.mediaroom.com/2021-09-15-Lilly-to-supply-388,000-doses-of-etesevimab-to-U-S-government-for-treatment-of-COVID-19\n",
      "http://lilly.mediaroom.com/2021-09-13-Lilly-to-Participate-in-the-2021-Cantor-Virtual-Global-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2021-09-13-Lilly-to-Present-New-Data-from-Oncology-Portfolio-at-ESMO-Congress\n",
      "http://lilly.mediaroom.com/2021-09-09-Lilly-Prices-First-Sustainability-Bond-to-Advance-Global-ESG-Strategy\n",
      "http://lilly.mediaroom.com/2021-09-09-FDA-grants-Jardiance-R-Breakthrough-Therapy-designation-for-heart-failure-with-preserved-ejection-fraction\n",
      "http://lilly.mediaroom.com/2021-09-07-Lilly-Diabetes-joins-The-Leona-M-and-Harry-B-Helmsley-Charitable-Trust-to-pledge-significant-funding-to-Type-1-Diabetes-Camps-Initiative\n",
      "http://lilly.mediaroom.com/2021-09-07-Lilly-Announces-Cash-Tender-Offer-for-Up-to-1-5-Billion-Combined-Aggregate-Principal-Amount-of-Its-Outstanding-Debt-Securities\n",
      "http://lilly.mediaroom.com/2021-09-03-Lilly-to-Participate-in-the-Morgan-Stanley-19th-Annual-Global-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2021-08-31-Lilly-to-Participate-in-Citis-16th-Annual-BioPharma-Virtual-Conference\n",
      "http://lilly.mediaroom.com/2021-08-27-Landmark-trial-demonstrates-Jardiance-R-empagliflozin-is-the-first-therapy-to-show-statistically-significant-improvement-in-heart-failure-outcomes-in-adults-with-preserved-ejection-fraction\n",
      "http://lilly.mediaroom.com/2021-08-25-Lilly-and-Lycia-Therapeutics-Enter-into-Strategic-Collaboration-to-Discover-and-Develop-Novel-Lysosomal-Targeting-Chimera-LYTAC-Degraders\n",
      "http://lilly.mediaroom.com/2021-08-25-Lilly-Announces-that-Professor-Carolyn-Bertozzi-has-Resigned-from-its-Board-of-Directors\n",
      "http://lilly.mediaroom.com/2021-08-18-US-FDA-approves-Jardiance-R-empagliflozin-to-treat-adults-living-with-heart-failure-with-reduced-ejection-fraction\n",
      "http://lilly.mediaroom.com/2021-08-17-Lilly-Announces-Leadership-Changes-and-Formation-of-Neuroscience-and-Immunology-Business-Units\n",
      "http://lilly.mediaroom.com/2021-08-16-FDA-approves-Lyumjev-R-insulin-lispro-aabc-injection-100-units-mL-for-use-in-insulin-pumps\n",
      "http://lilly.mediaroom.com/2021-08-16-Lillys-lebrikizumab-significantly-improved-skin-clearance-and-itch-in-people-with-moderate-to-severe-atopic-dermatitis-in-two-Phase-3-trials\n",
      "http://lilly.mediaroom.com/2021-08-03-Lilly-Delivers-Strong-Second-Quarter-2021-Financial-Results,-Updates-2021-Financial-Guidance\n",
      "http://lilly.mediaroom.com/2021-08-03-Lilly-and-Incytes-baricitinib-reduced-deaths-among-patients-with-COVID-19-receiving-invasive-mechanical-ventilation\n",
      "http://lilly.mediaroom.com/2021-07-29-Lilly-releases-donanemab-data-that-demonstrated-relationship-between-reduction-of-amyloid-plaque-and-slowing-of-cognitive-decline\n",
      "http://lilly.mediaroom.com/2021-07-29-FDA-broadens-existing-emergency-use-of-Lilly-and-Incytes-baricitinib-in-patients-hospitalized-with-COVID-19-requiring-oxygen\n",
      "http://lilly.mediaroom.com/2021-07-29-Lilly-and-Kumquat-Biosciences-Announce-Collaboration-to-Discover-and-Develop-Novel-Small-Molecules-that-Stimulate-Tumor-Specific-Immune-Responses\n",
      "http://lilly.mediaroom.com/2021-07-22-Lilly-Confirms-Date-and-Conference-Call-for-Second-Quarter-2021-Financial-Results-Announcement\n",
      "http://lilly.mediaroom.com/2021-07-16-Lilly-and-Incyte-provide-update-on-supplemental-New-Drug-Application-for-baricitinib-for-the-treatment-of-moderate-to-severe-atopic-dermatitis\n",
      "http://lilly.mediaroom.com/2021-07-15-Lilly-and-Banner-Alzheimers-Institute-collaborate-on-planned-Phase-3-prevention-trial-of-donanemab\n",
      "http://lilly.mediaroom.com/2021-07-14-Lilly-Announces-Acquisition-of-Protomer-Technologies\n",
      "http://lilly.mediaroom.com/2021-07-09-Mirikizumab-Up-Regulates-Genes-Associated-with-Mucosal-Healing-in-Ulcerative-Colitis-for-Up-to-One-Year-in-Phase-2-Study\n",
      "http://lilly.mediaroom.com/2021-07-06-Breakthrough-results-for-Jardiance-R-empagliflozin-confirm-EMPEROR-Preserved-as-first-and-only-successful-trial-for-heart-failure-with-preserved-ejection-fraction\n",
      "http://lilly.mediaroom.com/2021-06-29-Lilly-Declares-Third-Quarter-2021-Dividend\n",
      "http://lilly.mediaroom.com/2021-06-26-Lillys-SURPASS-1-results-published-in-The-Lancet-show-tirzepatides-superior-A1C-and-body-weight-reductions-versus-placebo-in-adults-with-type-2-diabetes\n",
      "http://lilly.mediaroom.com/2021-06-25-Lillys-SURPASS-2-results-published-in-The-New-England-Journal-of-Medicine-show-tirzepatide-achieved-superior-A1C-and-body-weight-reductions-compared-to-injectable-semaglutide-in-adults-with-type-2-diabetes\n",
      "http://lilly.mediaroom.com/2021-06-24-Lilly-announces-call-for-Leonard-Award-nominations-as-part-of-global-initiative-celebrating-100-years-of-insulin\n",
      "http://lilly.mediaroom.com/2021-06-24-Lillys-donanemab-receives-U-S-FDAs-Breakthrough-Therapy-designation-for-treatment-of-Alzheimers-disease\n",
      "http://lilly.mediaroom.com/2021-06-17-Lilly-Launches-Think-Talk-Treat-Migraine-TM-to-Help-Improve-Diagnosis-and-Treatment-of-Migraine\n",
      "http://lilly.mediaroom.com/2021-06-15-Lilly-Announces-Head-to-Head-Study-Comparing-Once-Monthly-Emgality-R-with-Every-Other-Day-Nurtec-R-ODT-for-the-Preventive-Treatment-of-Migraine\n",
      "http://lilly.mediaroom.com/2021-06-14-Lilly-to-Participate-in-Guggenheim-Biopharma-Strategy-Series\n",
      "http://lilly.mediaroom.com/2021-06-11-Lilly-Announces-Webcast-to-Provide-Diabetes-Portfolio-Update-at-ADA\n",
      "http://lilly.mediaroom.com/2021-06-04-Lilly-Announces-New-Clinical-Data-from-Verzenio-and-Oral-SERD-Programs-at-the-American-Society-of-Clinical-Oncology-Annual-Meeting\n",
      "http://lilly.mediaroom.com/2021-06-03-Lilly-to-Participate-in-Goldman-Sachs-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2021-06-03-Lilly-Reveals-Critical-Barriers-to-Optimal-Migraine-Care-and-Insights-From-Novel-Clinical-and-Patient-Centric-Real-World-Evidence,-Supporting-Lillys-Preventive-and-Acute-Treatment-Portfolio-at-AHS-2021\n",
      "http://lilly.mediaroom.com/2021-06-01-OLUMIANT-R-Improved-Pain,-Physical-Function-and-Morning-Joint-Stiffness-in-Rheumatoid-Arthritis-in-Phase-3-Post-Hoc-Analyses\n",
      "http://lilly.mediaroom.com/2021-06-01-Taltz-R-Showed-Consistent,-Long-Term-Improvement-in-Key-Signs-and-Symptoms-of-Axial-Spondyloarthritis-Through-Two-Years-in-Phase-3-Study\n",
      "http://lilly.mediaroom.com/2021-05-22-Mirikizumab-Improves-Fatigue-in-Patients-with-Crohns-Disease-in-Phase-2-Trial\n",
      "http://lilly.mediaroom.com/2021-05-20-Lillys-tirzepatide-achieves-all-primary-and-key-secondary-study-outcomes-against-insulin-glargine-in-adults-with-type-2-diabetes-and-increased-cardiovascular-risk-in-SURPASS-4-trial\n",
      "http://lilly.mediaroom.com/2021-05-19-Lilly-Announces-Details-of-Presentations-at-2021-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting\n",
      "http://lilly.mediaroom.com/index.php?s=9042&item=138226\n",
      "http://lilly.mediaroom.com/2021-05-13-Lilly-to-Participate-in-UBS-Global-Healthcare-Virtual-Conference\n",
      "http://lilly.mediaroom.com/2021-05-11-Lilly-and-MiNA-Therapeutics-Announce-saRNA-Research-Collaboration\n",
      "http://lilly.mediaroom.com/2021-05-06-Lilly-collaborates-internationally-with-leading-diabetes-technology-companies-to-integrate-connected-insulin-pen-solutions-for-people-with-diabetes\n",
      "http://lilly.mediaroom.com/2021-05-05-Lilly-to-Participate-in-Bank-of-America-Securities-2021-Health-Care-Conference\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "http://lilly.mediaroom.com/2021-05-04-Lilly-plans-donation-of-COVID-19-therapies-to-Direct-Relief-for-use-in-low-and-lower-middle-income-countries\n",
      "http://lilly.mediaroom.com/2021-05-04-Lilly-Outlines-Robust-Plans-to-Strengthen-ESG-Commitments-Across-the-Globe\n",
      "http://lilly.mediaroom.com/2021-05-04-Lilly-accelerating-baricitinibs-availability-in-India-following-receipt-of-permission-for-restricted-emergency-use-as-a-COVID-19-therapy-via-donations-and-licensing-agreements\n",
      "http://lilly.mediaroom.com/2021-05-03-Lilly-Declares-Second-Quarter-2021-Dividend-and-Announces-Additional-Share-Repurchase-Authorization\n",
      "http://lilly.mediaroom.com/2021-05-03-Lilly-to-Commit-5-Million-to-Direct-Reliefs-Fund-for-Health-Equity\n",
      "http://lilly.mediaroom.com/2021-04-27-Lilly-Delivers-First-Quarter-2021-Financial-Results,-Adjusts-2021-Financial-Guidance\n",
      "http://lilly.mediaroom.com/2021-04-23-OLUMIANT-R-Showed-Significant-Improvements-in-the-Severity-and-Extent-of-Atopic-Dermatitis-and-Other-Patient-Reported-Outcomes-in-Phase-3-Study-Analyses\n",
      "http://lilly.mediaroom.com/2021-04-23-Taltz-R-Delivers-More-Cumulative-Days-with-Completely-Clear-Skin-for-Adults-with-Psoriasis-Compared-to-Seven-Other-Biologics-in-Novel-Network-Meta-Analysis\n",
      "http://lilly.mediaroom.com/2021-04-20-Lilly-and-Incytes-Baricitinib-Improved-Hair-Regrowth-for-Alopecia-Areata-Patients-in-Second-Phase-3-Study\n",
      "http://lilly.mediaroom.com/2021-04-16-Lilly-requests-revocation-of-emergency-use-authorization-for-bamlanivimab-alone-to-complete-transition-to-bamlanivimab-and-etesevimab-together-for-treatment-of-COVID-19-in-the-U-S\n",
      "http://lilly.mediaroom.com/2021-04-13-Diogo-Rau-to-join-Lilly-as-Senior-Vice-President-and-Chief-Information-and-Digital-Officer\n",
      "http://lilly.mediaroom.com/2021-04-12-Lilly-modified-COVID-19-purchase-agreement-for-bamlanivimab-alone-with-the-U-S-government-and-is-focusing-on-supply-of-bamlanivimab-and-etesevimab-together\n",
      "http://lilly.mediaroom.com/2021-04-11-Lilly-Presents-New-Data-on-Retevmo-R-selpercatinib-in-Advanced-RET-Fusion-Positive-Gastrointestinal-and-Other-Cancers-at-2021-American-Association-for-Cancer-Research-AACR-Annual-Meeting\n",
      "http://lilly.mediaroom.com/2021-04-08-Lilly-and-Incyte-announce-results-from-the-Phase-3-COV-BARRIER-study-of-baricitinib-in-hospitalized-COVID-19-patients\n",
      "http://lilly.mediaroom.com/2021-04-06-Lilly-and-Incyte-communicate-review-extension-of-supplemental-New-Drug-Application-for-baricitinib-for-the-treatment-of-moderate-to-severe-atopic-dermatitis\n",
      "http://lilly.mediaroom.com/2021-04-06-Lilly-Confirms-Date-and-Conference-Call-for-First-Quarter-2021-Financial-Results-Announcement\n",
      "http://lilly.mediaroom.com/2021-04-01-Lilly-to-Host-Sustainability-Webcast-to-Provide-Overview-of-Environmental-Social-and-Governance-ESG-Efforts\n",
      "http://lilly.mediaroom.com/2021-03-31-Survey-reveals-healthcare-professionals-believe-greater-collaboration-is-needed-to-improve-patient-outcomes-in-diabetes-care\n",
      "http://lilly.mediaroom.com/2021-03-29-Lilly-Vir-Biotechnology-and-GSK-Announce-Positive-Topline-Data-from-the-Phase-2-BLAZE-4-Trial-Evaluating-Bamlanivimab-with-VIR-7831-in-Low-Risk-Adults-with-COVID-19\n",
      "http://lilly.mediaroom.com/index.php?s=9042&item=138180\n",
      "http://lilly.mediaroom.com/2021-03-17-Lilly-Presents-Patient-Reported-Outcomes-from-the-Positive-Phase-3-monarchE-Trial-for-Verzenio-R-at-St-Gallen-Virtual-Congress-2021\n",
      "http://lilly.mediaroom.com/2021-03-16-Lillys-Mirikizumab-Helps-Patients-Achieve-Clinical-Remission-and-Improves-Symptoms-in-Adults-with-Ulcerative-Colitis-in-12-Week-Phase-3-Induction-Study\n",
      "http://lilly.mediaroom.com/2021-03-13-Lillys-donanemab-slowed-Alzheimers-disease-progression-in-Phase-2-trial-full-data-presented-at-AD-PD-TM-2021-and-published-in-NEJM\n",
      "http://lilly.mediaroom.com/2021-03-10-Lilly-Announces-Details-of-Presentations-at-2021-American-Association-for-Cancer-Research-AACR\n",
      "http://lilly.mediaroom.com/2021-03-10-Lillys-bamlanivimab-and-etesevimab-together-reduced-hospitalizations-and-death-in-Phase-3-trial-for-early-COVID-19\n",
      "http://lilly.mediaroom.com/2021-03-09-Data-from-Lilly-at-International-Conference-on-Alzheimers-Parkinson-Diseases-2021-TM-AD-PD-TM-2021-to-Showcase-Clinical-Advances-in-Alzheimers-Disease-Research\n",
      "http://lilly.mediaroom.com/2021-03-09-Lilly-Announces-Leadership-Transitions-in-Manufacturing-and-Ethics-and-Compliance-Organizations\n",
      "http://lilly.mediaroom.com/2021-03-08-Lilly-and-Biolojic-Design-Announce-Research-Collaboration-to-Discover-and-Develop-Antibody-Therapies-for-Diabetes\n",
      "http://lilly.mediaroom.com/2021-03-08-Lilly-to-Participate-in-Barclays-Global-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2021-03-05-EMA-issues-advice-on-Lillys-bamlanivimab-LY-CoV555-alone-and-administered-together-with-etesevimab-LY-CoV016-for-the-treatment-of-confirmed-COVID-19-in-the-European-Union\n",
      "http://lilly.mediaroom.com/2021-03-05-Loxo-Oncology-at-Lilly-Announces-Publication-of-Pirtobrutinib-LOXO-305-Phase-1-2-Data-in-The-Lancet\n",
      "http://lilly.mediaroom.com/2021-03-04-Tirzepatide-achieved-superior-A1C-and-body-weight-reductions-across-all-three-doses-compared-to-injectable-semaglutide-in-adults-with-type-2-diabetes\n",
      "http://lilly.mediaroom.com/2021-03-03-Baricitinib-is-First-JAK-Inhibitor-to-Demonstrate-Hair-Regrowth-in-Phase-3-Alopecia-Areata-AA-Trial\n",
      "http://lilly.mediaroom.com/2021-02-26-Lilly-announces-additional-doses-of-neutralizing-antibody-therapy-purchased-by-U-S-government-to-treat-COVID-19\n",
      "http://lilly.mediaroom.com/2021-02-25-Welldoc-and-Lilly-collaborate-to-integrate-BlueStar-R-app-capabilities-into-Lillys-connected-insulin-solutions\n",
      "http://lilly.mediaroom.com/2021-02-24-Lilly-to-Participate-in-Cowen-Health-Care-Conference\n",
      "http://lilly.mediaroom.com/2021-02-18-Lilly-and-Rigel-Enter-Strategic-Collaboration-to-Develop-RIPK1-Inhibitors-for-the-Potential-Treatment-of-Immunological-and-Neurodegenerative-Diseases\n",
      "http://lilly.mediaroom.com/2021-02-17-Tirzepatide-significantly-reduced-A1C-and-body-weight-in-people-with-type-2-diabetes-in-two-phase-3-trials-from-Lillys-SURPASS-program\n",
      "http://lilly.mediaroom.com/2021-02-17-Kimberly-H-Johnson-Elected-to-Lilly-Board-of-Directors\n",
      "http://lilly.mediaroom.com/2021-02-11-Lilly-To-Participate-in-SVB-Leerink-Global-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2021-02-09-Lillys-bamlanivimab-LY-CoV555-administered-with-etesevimab-LY-CoV016-receives-FDA-emergency-use-authorization-for-COVID-19\n",
      "http://lilly.mediaroom.com/2021-02-09-Lilly-Appoints-Anat-Ashkenazi-Chief-Financial-Officer\n",
      "http://lilly.mediaroom.com/2021-02-04-Lilly-Announces-Webcast-to-Provide-Alzheimers-Disease-Update-at-AD-PD-Conference\n",
      "http://lilly.mediaroom.com/2021-02-03-Lilly-to-Participate-in-Guggenheim-Healthcare-Talks-2021-Oncology-Day\n",
      "http://lilly.mediaroom.com/2021-02-01-Lilly-Partners-with-Area-Health-Systems-to-Help-Enable-Access-to-Important-Antibody-Infusion-Therapies-for-COVID-19-Patients\n",
      "http://lilly.mediaroom.com/2021-01-29-Lilly-Reports-Strong-Fourth-Quarter-and-Full-Year-2020-Financial-Results\n",
      "http://lilly.mediaroom.com/2021-01-28-Lilly-and-Asahi-Kasei-Pharma-Announce-License-Agreement-for-Chronic-Pain-Drug-Candidate\n",
      "http://lilly.mediaroom.com/2021-01-27-Lilly-Vir-Biotechnology-and-GSK-announce-first-patient-dosed-in-expanded-BLAZE-4-trial-evaluating-bamlanivimab-LY-CoV555-with-VIR-7831-GSK4182136-for-COVID-19\n",
      "http://lilly.mediaroom.com/2021-01-26-New-data-show-treatment-with-Lillys-neutralizing-antibodies-bamlanivimab-LY-CoV555-and-etesevimab-LY-CoV016-together-reduced-risk-of-COVID-19-hospitalizations-and-death-by-70-percent\n",
      "http://lilly.mediaroom.com/2021-01-22-Lilly-Completes-Acquisition-of-Prevail-Therapeutics\n",
      "http://lilly.mediaroom.com/2021-01-21-Lillys-neutralizing-antibody-bamlanivimab-LY-CoV555-prevented-COVID-19-at-nursing-homes-in-the-BLAZE-2-trial-reducing-risk-by-up-to-80-percent-for-residents\n",
      "http://lilly.mediaroom.com/2021-01-19-Lilly-and-Merus-NV-Announce-Collaboration-to-Discover-Novel-T-Cell-Re-Directing-Bispecific-Antibodies\n",
      "http://lilly.mediaroom.com/2021-01-15-Lilly-Confirms-Date-and-Conference-Call-for-Fourth-Quarter-2020-Financial-Results-Announcement\n",
      "http://lilly.mediaroom.com/2021-01-15-Lilly-Announces-30-Million-Limited-Partner-Investment-in-Unseen-Capital-Health-Fund\n",
      "http://lilly.mediaroom.com/2021-01-14-Gabrielle-Sulzberger-Elected-to-Lilly-Board-of-Directors\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "http://lilly.mediaroom.com/2021-01-11-US-FDA-accepts-supplemental-New-Drug-Application-for-Jardiance-R-empagliflozin-for-adults-with-heart-failure-with-reduced-ejection-fraction\n",
      "http://lilly.mediaroom.com/2021-01-11-Lillys-Donanemab-Slows-Clinical-Decline-of-Alzheimers-Disease-in-Positive-Phase-2-Trial\n",
      "http://lilly.mediaroom.com/2021-01-04-Lilly-to-Participate-in-J-P-Morgan-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2020-12-18-Lilly-to-begin-pragmatic-study-of-neutralizing-antibody-bamlanivimab-LY-CoV555-for-COVID-19-in-New-Mexico\n",
      "http://lilly.mediaroom.com/2020-12-15-Lilly-Announces-2021-Financial-Guidance-Updates-2020-Guidance\n",
      "http://lilly.mediaroom.com/2020-12-15-Lilly-Announces-Agreement-to-Acquire-Prevail-Therapeutics\n",
      "http://lilly.mediaroom.com/2020-12-14-Lilly-Announces-15-Percent-Dividend-Increase\n",
      "http://lilly.mediaroom.com/2020-12-14-Lilly-announces-opening-of-patient-enrollment-for-New-IDEAS-Imaging-Dementia-Evidence-for-Amyloid-Scanning-study\n",
      "http://lilly.mediaroom.com/2020-12-11-Data-from-ACTT-2-Trial-of-Baricitinib-in-Hospitalized-COVID-19-Patients-Supportive-of-the-EUA-Published-in-New-England-Journal-of-Medicine\n",
      "http://lilly.mediaroom.com/2020-12-09-Lilly-Presents-Positive-Primary-Outcome-Data-from-monarchE-that-Builds-on-Previous-Definitive-Analysis-for-Verzenio-R\n",
      "http://lilly.mediaroom.com/2020-12-09-Lillys-tirzepatide-significantly-reduced-A1C-and-body-weight-in-people-with-type-2-diabetes\n",
      "http://lilly.mediaroom.com/2020-12-08-Lilly-Confirms-Date-and-Conference-Call-for-2021-Financial-Guidance-Announcement\n",
      "http://lilly.mediaroom.com/2020-12-07-Loxo-Oncology-at-Lilly-Announces-Updated-Data-from-the-Phase-1-2-BRUIN-Clinical-Trial-for-LOXO-305-in-Chronic-Lymphocytic-Leukemia-and-Small-Lymphocytic-Lymphoma-at-the-American-Society-of-Hematology-Annual-Meeting\n",
      "http://lilly.mediaroom.com/2020-12-05-Loxo-Oncology-at-Lilly-Announces-Updated-Data-from-the-Phase-1-2-BRUIN-Clinical-Trial-for-LOXO-305-in-Mantle-Cell-Lymphoma-and-Non-Hodgkin-Lymphomas-at-the-American-Society-of-Hematology-ASH-Annual-Meeting\n",
      "http://lilly.mediaroom.com/2020-12-04-Lilly-and-UnitedHealth-Group-partner-on-pragmatic-study-of-neutralizing-antibody-bamlanivimab-LY-CoV555-for-COVID-19\n",
      "http://lilly.mediaroom.com/2020-12-02-Lilly-announces-650-000-additional-doses-of-neutralizing-antibody-bamlanivimab-LY-CoV555-purchased-by-U-S-government-to-treat-COVID-19\n",
      "http://lilly.mediaroom.com/2020-11-24-Lilly-to-Participate-in-Evercore-ISI-3rd-Annual-HealthCONx-Conference\n",
      "http://lilly.mediaroom.com/2020-11-20-Lillys-neutralizing-antibody-bamlanivimab-LY-CoV555-receives-interim-authorization-from-Health-Canada-as-a-treatment-for-COVID-19\n",
      "http://lilly.mediaroom.com/2020-11-20-Lilly-and-Precision-BioSciences-Announce-Genome-Editing-Research-Collaboration-and-License-Agreement\n",
      "http://lilly.mediaroom.com/2020-11-19-Baricitinib-Receives-Emergency-Use-Authorization-from-the-FDA-for-the-Treatment-of-Hospitalized-Patients-with-COVID-19\n",
      "http://lilly.mediaroom.com/2020-11-19-Lilly-and-Ypsomed-collaborate-to-advance-an-automated-insulin-delivery-system-for-people-with-diabetes\n",
      "http://lilly.mediaroom.com/2020-11-18-Jardiance-R-reduced-the-risk-of-first-plus-recurrent-cardiovascular-events-in-adults-with-type-2-diabetes-and-established-cardiovascular-disease-in-new-analysis-from-the-EMPA-REG-OUTCOME-R-trial\n",
      "http://lilly.mediaroom.com/2020-11-12-Lilly-to-Participate-in-Wolfe-Research-Virtual-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2020-11-12-Lilly-to-Participate-in-Bernstein-Operational-Decisions-Conference\n",
      "http://lilly.mediaroom.com/2020-11-11-Lilly-Announces-Webcast-to-Provide-an-Overview-of-Tirzepatide-Phase-3-clinical-program\n",
      "http://lilly.mediaroom.com/2020-11-09-Lillys-neutralizing-antibody-bamlanivimab-LY-CoV555-receives-FDA-emergency-use-authorization-for-the-treatment-of-recently-diagnosed-COVID-19\n",
      "http://lilly.mediaroom.com/2020-11-05-Loxo-Oncology-at-Lilly-Announces-Details-of-LOXO-305-Presentations-at-the-2020-American-Society-of-Hematology-ASH-Annual-Meeting\n",
      "http://lilly.mediaroom.com/2020-11-05-Aarti-Shah-to-Retire-as-Lilly-Chief-Information-and-Digital-Officer\n",
      "http://lilly.mediaroom.com/2020-11-02-ACR-2020-Lilly-and-Incyte-Highlight-Positive-Data-for-Olumiant-R-in-Rheumatoid-Arthritis\n",
      "http://lilly.mediaroom.com/2020-10-31-EADV-2020-Lilly-and-Incyte-Showcase-New-Data-for-Baricitinib-for-the-Treatment-of-Moderate-to-Severe-Atopic-Dermatitis\n",
      "http://lilly.mediaroom.com/2020-10-30-Fall-Clinical-Dermatology-2020-Lilly-and-Incyte-Showcase-Positive-New-Data-for-Baricitinib-in-Adult-Patients-with-Alopecia-Areata\n",
      "http://lilly.mediaroom.com/2020-10-29-New-Data-at-EADV-2020-Confirm-Taltz-R-ixekizumab-Demonstrates-Sustained-Long-Term-Efficacy-in-Patients-with-Psoriasis-and-Psoriatic-Arthritis\n",
      "http://lilly.mediaroom.com/2020-10-28-Data-for-Lillys-bamlanivimab-LY-CoV555-in-COVID-19-outpatients-published-in-New-England-Journal-of-Medicine\n",
      "http://lilly.mediaroom.com/2020-10-28-Lilly-announces-agreement-with-U-S-government-to-supply-300-000-vials-of-investigational-neutralizing-antibody-bamlanivimab-LY-CoV555-in-an-effort-to-fight-COVID-19\n",
      "http://lilly.mediaroom.com/2020-10-27-Lilly-Reports-Third-Quarter-Financial-Results-Updates-Guidance\n",
      "http://lilly.mediaroom.com/2020-10-23-New-Jardiance-R-findings-showed-improved-cardio-renal-outcomes-in-adults-with-heart-failure-with-reduced-ejection-fraction-regardless-of-chronic-kidney-disease-status\n",
      "http://lilly.mediaroom.com/2020-10-19-Lilly-Declares-Fourth-Quarter-2020-Dividend\n",
      "http://lilly.mediaroom.com/2020-10-15-Lilly-Announces-Agreement-to-Acquire-Disarm-Therapeutics\n",
      "http://lilly.mediaroom.com/2020-10-12-Mirikizumab-Shows-Continued-Symptom-Improvement-and-Reduction-of-Intestinal-Inflammation-in-Patients-with-Crohns-Disease-in-52-Week-Phase-2-Trial\n",
      "http://lilly.mediaroom.com/2020-10-09-Lillys-OVERCOME-Study-Reveals-Nearly-80-of-People-Reported-Improvement-in-Their-Migraine-Since-Starting-a-CGRP-Monoclonal-Antibody-for-Preventive-Treatment\n",
      "http://lilly.mediaroom.com/2020-10-08-Lilly-Confirms-Date-and-Conference-Call-for-Third-Quarter-2020-Financial-Results-Announcement\n",
      "http://lilly.mediaroom.com/2020-10-08-Baricitinib-has-Significant-Effect-on-Recovery-Time-Most-Impactful-in-COVID-19-Patients-Requiring-Oxygen\n",
      "http://lilly.mediaroom.com/2020-10-08-Indy-Racial-Equity-Pledge-Launches-to-Drive-Accountability-Action-and-Progress-on-Racial-Equity\n",
      "http://lilly.mediaroom.com/2020-10-08-Lilly-Announces-Arrangement-for-Supply-of-Potential-COVID-19-Antibody-Therapy-for-Low-and-Middle-Income-Countries\n",
      "http://lilly.mediaroom.com/2020-10-07-Lilly-provides-comprehensive-update-on-progress-of-SARS-CoV-2-neutralizing-antibody-programs\n",
      "http://lilly.mediaroom.com/2020-10-07-Lilly-and-Dexcom-team-up-on-new-program-to-help-improve-diabetes-management\n",
      "http://lilly.mediaroom.com/2020-10-06-REYVOW-R-lasmiditan-C-V-Demonstrated-Superior-Pain-Freedom-At-2-Hours-in-At-Least-2-of-3-Migraine-Attacks-in-New-Phase-3-Consistency-of-Effect-Study\n",
      "http://lilly.mediaroom.com/2020-09-20-Verzenio-R-Significantly-Reduced-the-Risk-of-Cancer-Recurrence-by-25-for-People-with-HR-HER2-High-Risk-Early-Breast-Cancer\n",
      "http://lilly.mediaroom.com/2020-09-18-CHMP-Recommends-Approval-of-Lillys-Baricitinib-for-the-Treatment-of-Adults-with-Moderate-to-Severe-Atopic-Dermatitis\n",
      "http://lilly.mediaroom.com/2020-09-17-Lilly-and-Amgen-Announce-Manufacturing-Collaboration-for-COVID-19-Antibody-Therapies\n",
      "http://lilly.mediaroom.com/2020-09-16-Lilly-announces-proof-of-concept-data-for-neutralizing-antibody-LY-CoV555-in-the-COVID-19-outpatient-setting\n",
      "http://lilly.mediaroom.com/2020-09-15-Lilly-Launches-Digital-Health-Open-Innovation-Challenge-to-Help-Transform-Atopic-Dermatitis-Care\n",
      "http://lilly.mediaroom.com/2020-09-15-US-FDA-grants-Fast-Track-designation-to-Jardiance-R-empagliflozin-to-improve-outcomes-following-a-heart-attack\n",
      "http://lilly.mediaroom.com/2020-09-14-Baricitinib-in-Combination-with-Remdesivir-Reduces-Time-to-Recovery-in-Hospitalized-Patients-with-COVID-19-in-NIAID-Sponsored-ACTT-2-Trial\n",
      "http://lilly.mediaroom.com/2020-09-11-Lilly-to-Participate-in-Cantor-Fitzgerald-Virtual-Global-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2020-09-11-Lilly-to-Participate-in-Morgan-Stanley-Global-Healthcare-Conference\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "http://lilly.mediaroom.com/2020-09-11-REYVOW-TM-lasmiditan-C-V-Demonstrated-Pain-Freedom-from-Migraine-Attacks-At-60-Minutes-and-Up-to-48-Hours-in-New-Phase-3-Study\n",
      "http://lilly.mediaroom.com/2020-09-10-Lilly-Announces-Webcast-to-Discuss-ESMO-2020-Presentations\n",
      "http://lilly.mediaroom.com/2020-09-10-Lilly-commits-Insulin-Value-Program-featuring-35-copay-card-to-suite-of-affordability-solutions-for-people-with-diabetes\n",
      "http://lilly.mediaroom.com/2020-09-10-Lilly-Oncology-to-Showcase-New-Data-from-Robust-Cancer-Research-Pipeline-at-ESMO-Virtual-Congress-2020\n",
      "http://lilly.mediaroom.com/2020-09-09-Lilly-Announces-Leadership-Changes\n",
      "http://lilly.mediaroom.com/2020-09-03-FDA-approves-additional-doses-of-Trulicity-R-dulaglutide-for-the-treatment-of-type-2-diabetes\n",
      "http://lilly.mediaroom.com/2020-08-29-Jardiance-R-reduced-the-combined-relative-risk-of-cardiovascular-death-and-hospitalization-for-heart-failure-by-25-in-adults-with-and-without-diabetes-who-had-heart-failure-with-reduced-ejection-fraction\n",
      "http://lilly.mediaroom.com/2020-08-27-New-England-Journal-of-Medicine-Publishes-Phase-1-2-Data-for-Retevmo-TM-selpercatinib-in-Advanced-RET-Driven-Lung-and-Thyroid-Cancers\n",
      "http://lilly.mediaroom.com/2020-08-18-Lilly-and-Innovent-Announce-Global-Expansion-of-TYVYT-Licensing-Agreement\n",
      "http://lilly.mediaroom.com/2020-08-03-Lilly-Initiates-Phase-3-Trial-of-LY-CoV555-for-Prevention-of-COVID-19-at-Long-Term-Care-Facilities-in-Partnership-with-the-National-Institute-of-Allergy-and-Infectious-Diseases-NIAID\n",
      "http://lilly.mediaroom.com/2020-07-30-Lilly-Reports-Second-Quarter-Financial-Results-Raises-EPS-Guidance\n",
      "http://lilly.mediaroom.com/2020-07-30-Jardiance-R-meets-primary-endpoint-in-reducing-risk-of-cardiovascular-death-or-hospitalization-for-heart-failure-in-phase-III-trial-in-adults-with-and-without-diabetes\n",
      "http://lilly.mediaroom.com/2020-07-28-Lillys-P-tau217-Blood-Test-Shows-High-Accuracy-in-Diagnosis-of-Alzheimers-Disease-in-Data-Published-in-JAMA\n",
      "http://lilly.mediaroom.com/2020-07-21-Data-from-Lilly-at-Alzheimers-Association-International-Conference-2020-R-AAIC-R-2020-to-Showcase-Clinical-Advances-in-Alzheimers-Research\n",
      "http://lilly.mediaroom.com/2020-07-17-Lilly-Confirms-Date-and-Conference-Call-for-Second-Quarter-2020-Financial-Results-Announcement\n",
      "http://lilly.mediaroom.com/2020-07-17-Lillys-Mirikizumab-Superior-to-Cosentyx-R-secukinumab-in-a-Phase-3-Study-for-Patients-with-Moderate-to-Severe-Plaque-Psoriasis\n",
      "http://lilly.mediaroom.com/2020-07-15-Lilly-Declares-Third-Quarter-2020-Dividend\n",
      "http://lilly.mediaroom.com/2020-06-25-Central-Indiana-Racial-Equity-Fund-Launches-with-more-than-2-2-Million-in-Initial-Commitments\n",
      "http://lilly.mediaroom.com/2020-06-24-Lilly-launches-program-about-what-people-with-diabetes-should-Know-Before-the-Low\n",
      "http://lilly.mediaroom.com/2020-06-19-Full-results-from-EMPERIAL-exercise-ability-trials-presented\n",
      "http://lilly.mediaroom.com/2020-06-17-Emgality-R-Demonstrates-Reduction-in-Frequency-Duration-and-Pain-Severity-in-Patients-with-Episodic-and-Chronic-Migraine\n",
      "http://lilly.mediaroom.com/2020-06-16-Lillys-OVERCOME-Study-Reveals-Less-than-30-Percent-of-People-Living-with-Migraine-Take-Recommended-Prescription-Medications\n",
      "http://lilly.mediaroom.com/2020-06-16-Verzenio-R-abemaciclib-Significantly-Reduced-the-Risk-of-Cancer-Returning-in-People-with-High-Risk-HR-HER2-Early-Breast-Cancer\n",
      "http://lilly.mediaroom.com/2020-06-15-Lilly-Begins-a-Phase-3-Clinical-Trial-with-Baricitinib-for-Hospitalized-COVID-19-Patients\n",
      "http://lilly.mediaroom.com/2020-06-13-Once-weekly-Trulicity-R-dulaglutide-demonstrates-significantly-higher-adherence-and-more-persistence-compared-to-once-weekly-semaglutide-and-exenatide-injections\n",
      "http://lilly.mediaroom.com/2020-06-13-Eli-Lilly-and-Company-Foundation-Pledges-25-Million-to-Combat-Racial-Injustice\n",
      "http://lilly.mediaroom.com/2020-06-12-Lilly-and-Dermira-Present-New-Lebrikizumab-Phase-2b-Clinical-Data-Showing-Patients-with-Atopic-Dermatitis-Had-Clinically-Meaningful-Improvements-in-Itch-Sleep-and-Quality-of-Life\n",
      "http://lilly.mediaroom.com/2020-06-12-Lilly-Highlights-the-Evolution-of-Its-Dermatology-Portfolio-at-Annual-American-Academy-of-Dermatology-Meeting-AAD\n",
      "http://lilly.mediaroom.com/2020-06-12-Lilly-Partners-with-Indianapolis-Recorder-Newspaper-Radio-One-and-WISH-TV-for-a-Day-of-Solidarity-Virtual-Event\n",
      "http://lilly.mediaroom.com/2020-06-09-First-patient-dose-delivered-for-Lillys-tirzepatide-cardiovascular-outcomes-trial\n",
      "http://lilly.mediaroom.com/2020-06-08-Lilly-to-Participate-in-Goldman-Sachs-Global-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2020-06-08-Lilly-Announces-Start-of-a-Phase-1-Study-for-its-Second-Potential-COVID-19-Antibody-Treatment\n",
      "http://lilly.mediaroom.com/2020-06-03-EULAR-2020-Lilly-Shares-New-Data-for-Olumiant-R-in-Rheumatoid-Arthritis-and-Systemic-Lupus-Erythematosus\n",
      "http://lilly.mediaroom.com/2020-06-03-EULAR-2020-Lillys-Taltz-R-ixekizumab-Continues-to-Show-Robust-and-Consistent-Efficacy-in-Psoriatic-Arthritis\n",
      "http://lilly.mediaroom.com/2020-06-01-Lillys-Taltz-R-ixekizumab-is-the-First-IL-17A-Antagonist-to-Receive-U-S-FDA-Approval-for-the-Treatment-of-Non-Radiographic-Axial-Spondyloarthritis-nr-axSpA\n",
      "http://lilly.mediaroom.com/2020-06-01-Lilly-Begins-Worlds-First-Study-of-a-Potential-COVID-19-Antibody-Treatment-in-Humans\n",
      "http://lilly.mediaroom.com/2020-05-29-Lillys-CYRAMZA-R-ramucirumab-Receives-FDA-Approval-as-First-Line-Treatment-for-Metastatic-EGFR-Mutated-Non-Small-Cell-Lung-Cancer\n",
      "http://lilly.mediaroom.com/2020-05-28-Lilly-Receives-U-S-FDA-Approval-of-TAUVID-TM-flortaucipir-F-18-injection-for-Use-in-Patients-Being-Evaluated-for-Alzheimers-Disease\n",
      "http://lilly.mediaroom.com/2020-05-26-Statement-from-Lilly-Chairman-and-CEO-Dave-Ricks-on-New-Part-D-Senior-Savings-Model\n",
      "http://lilly.mediaroom.com/2020-05-26-Boehringer-Ingelheim-and-Lilly-to-collaborate-with-Duke-Clinical-Research-Institute-on-a-pragmatic-trial-examining-Jardiances-R-effects-following-an-acute-myocardial-infarction\n",
      "http://lilly.mediaroom.com/2020-05-26-Emgality-R-Shows-Improvement-in-Work-Productivity-and-Health-and-Well-Being-Between-Attacks-in-Patients-with-Migraine-and-a-History-of-Preventive-Treatment-Failure\n",
      "http://lilly.mediaroom.com/2020-05-19-Results-of-GERAS-US-Study-Demonstrate-Societal-Cost-Burden-for-Patients-and-Caregivers-During-Early-Stages-of-Alzheimers-Disease\n",
      "http://lilly.mediaroom.com/2020-05-13-Lilly-Oncology-Showcases-Innovation-in-Cancer-Research-at-ASCO-2020\n",
      "http://lilly.mediaroom.com/2020-05-08-Lilly-Receives-U-S-FDA-Approval-for-Retevmo-TM-selpercatinib-the-First-Therapy-Specifically-for-Patients-with-Advanced-RET-Driven-Lung-and-Thyroid-Cancers\n",
      "http://lilly.mediaroom.com/2020-05-08-Higher-investigational-doses-of-Trulicity-R-dulaglutide-meaningfully-reduced-A1C-and-body-weight-in-people-with-type-2-diabetes\n",
      "http://lilly.mediaroom.com/2020-05-05-Lilly-to-Participate-in-UBS-Virtual-Global-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2020-05-04-Lilly-Declares-Second-Quarter-2020-Dividend\n",
      "http://lilly.mediaroom.com/2020-05-04-Lilly-and-Junshi-Biosciences-to-Co-develop-Antibody-Therapies-for-the-Prevention-and-Treatment-of-COVID-19\n",
      "http://lilly.mediaroom.com/2020-04-30-Lilly-to-Participate-in-Bank-of-America-Securities-Health-Care-Conference\n",
      "http://lilly.mediaroom.com/2020-04-23-Lilly-Reports-Strong-First-Quarter-Financial-Results-Adjusts-EPS-Guidance\n",
      "http://lilly.mediaroom.com/2020-04-16-Lower-priced-versions-of-Humalog-R-Mix75-25-TM-KwikPen-R-and-Humalog-R-Junior-KwikPen-R-now-available\n",
      "http://lilly.mediaroom.com/2020-04-10-Lilly-Begins-Clinical-Testing-of-Therapies-for-COVID-19\n",
      "http://lilly.mediaroom.com/2020-04-08-Lilly-Confirms-Date-and-Conference-Call-for-First-Quarter-2020-Financial-Results-Announcement\n",
      "http://lilly.mediaroom.com/2020-04-07-Eli-Lilly-and-Company-to-Hold-2020-Annual-Meeting-of-Shareholders-Virtually\n",
      "http://lilly.mediaroom.com/2020-04-07-New-35-Co-Pay-Now-Available-Through-Lilly-Insulin-Value-Program-in-Response-to-COVID-19-Crisis-in-U-S\n",
      "http://lilly.mediaroom.com/2020-04-01-Medical-Professionals-Across-Merck-Co-Inc-Pfizer-Inc-and-Eli-Lilly-and-Company-Activate-to-Support-Health-Systems-First-Responders-and-Patients-Amid-COVID-19-Pandemic\n",
      "http://lilly.mediaroom.com/2020-04-01-Governor-Holcomb-and-Mayor-Hogsett-announce-coalition-to-flatten-the-COVID-19-curve-across-state-public-invited-to-make-commitment\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "http://lilly.mediaroom.com/2020-03-31-Lilly-and-Sitryx-Announce-Licensing-and-Research-Collaboration-to-Discover-and-Develop-New-Immunometabolic-Medicines\n",
      "http://lilly.mediaroom.com/2020-03-30-Lillys-Taltz-R-ixekizumab-Receives-U-S-FDA-Approval-for-the-Treatment-of-Pediatric-Patients-with-Moderate-to-Severe-Plaque-Psoriasis\n",
      "http://lilly.mediaroom.com/2020-03-24-Updates-from-Lilly-about-insulin-supply-and-affordability\n",
      "http://lilly.mediaroom.com/2020-03-23-Lilly-Provides-Update-on-Clinical-Trial-Activities-During-COVID-19-Pandemic\n",
      "http://lilly.mediaroom.com/2020-03-22-Lilly-to-Provide-Drive-Through-COVID-19-Testing-for-Indianapolis-Health-Care-Workers\n",
      "http://lilly.mediaroom.com/2020-03-20-US-FDA-issues-complete-response-letter-for-empagliflozin-2-5-mg-as-adjunct-to-insulin-for-adults-with-type-1-diabetes\n",
      "http://lilly.mediaroom.com/2020-03-20-Kathryn-Beiser-to-join-Lilly-as-Vice-President-Global-Communications\n",
      "http://lilly.mediaroom.com/2020-03-18-Lilly-Indiana-State-Department-of-Health-Partner-to-Accelerate-COVID-19-Testing-Using-Lilly-Research-Laboratories\n",
      "http://lilly.mediaroom.com/2020-03-16-Lilly-Receives-FDA-Breakthrough-Therapy-Designation-for-Baricitinib-for-the-Treatment-of-Alopecia-Areata\n",
      "http://lilly.mediaroom.com/2020-03-12-AbCellera-and-Lilly-to-Co-develop-Antibody-Therapies-for-the-Treatment-of-COVID-19\n",
      "http://lilly.mediaroom.com/2020-03-12-US-FDA-grants-Fast-Track-designation-to-Jardiance-R-for-the-treatment-of-chronic-kidney-disease\n",
      "http://lilly.mediaroom.com/2020-03-11-Lilly-to-Participate-in-New-Model-Designed-to-Make-Insulins-More-Affordable-for-Seniors-in-Medicare-Part-D\n",
      "http://lilly.mediaroom.com/2020-03-09-Lilly-to-Participate-in-Barclays-Global-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2020-03-03-Lilly-Statement-on-Novel-Coronavirus-and-the-Reliable-Supply-of-the-Companys-Medicines\n",
      "http://lilly.mediaroom.com/2020-03-02-U-S-FDA-Accepts-Regulatory-Submission-for-Tanezumab-a-Potential-First-in-Class-Treatment-for-Patients-with-Chronic-Pain-Due-to-Moderate-to-Severe-Osteoarthritis\n",
      "http://lilly.mediaroom.com/2020-02-28-Eli-Lilly-and-Company-Statement-on-ICER-Final-Report-for-Acute-Treatments-for-Migraine-Effectiveness-and-Value\n",
      "http://lilly.mediaroom.com/2020-02-26-FDA-Advisory-Committee-Votes-in-Favor-of-Lillys-CYRAMZA-R-ramucirumab-as-First-Line-Treatment-for-Metastatic-EGFR-Mutated-Non-Small-Cell-Lung-Cancer\n",
      "http://lilly.mediaroom.com/2020-02-21-Trulicity-R-dulaglutide-is-the-first-and-only-type-2-diabetes-medicine-approved-to-reduce-cardiovascular-events-in-adults-with-and-without-established-cardiovascular-disease\n",
      "http://lilly.mediaroom.com/2020-02-21-Lilly-to-Participate-in-Cowen-Health-Care-Conference\n",
      "http://lilly.mediaroom.com/2020-02-21-Lilly-To-Participate-in-SVB-Leerink-Global-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2020-02-20-Lilly-Completes-Acquisition-of-Dermira\n",
      "http://lilly.mediaroom.com/2020-02-10-Lilly-Announces-Topline-Results-for-Solanezumab-from-the-Dominantly-Inherited-Alzheimer-Network-Trials-Unit-DIAN-TU-Study\n",
      "http://lilly.mediaroom.com/2020-02-07-Lilly-to-Participate-in-Guggenheim-Healthcare-Talks-Idea-Forum\n",
      "http://lilly.mediaroom.com/2020-01-31-Lillys-REYVOW-TM-lasmiditan-C-V-the-First-and-Only-Medicine-in-a-New-Class-of-Acute-Treatment-for-Migraine-ditan-Now-Available-for-Prescription\n",
      "http://lilly.mediaroom.com/2020-01-31-CHMP-Recommends-Approval-of-Lillys-New-Fast-Acting-Mealtime-Insulin-to-Improve-Glycemic-Control-in-Adults-with-Diabetes\n",
      "http://lilly.mediaroom.com/2020-01-30-Lilly-Reports-Strong-Fourth-Quarter-and-Full-Year-2019-Financial-Results-Updates-2020-Guidance-for-Pending-Dermira-Acquisition\n",
      "http://lilly.mediaroom.com/2020-01-30-Lilly-and-Incyte-Announce-Positive-Top-Line-Results-from-the-North-American-BREEZE-AD5-Phase-3-Study-of-Oral-Selective-JAK-Inhibitor-Baricitinib-in-Patients-with-Moderate-to-Severe-Atopic-Dermatitis\n",
      "http://lilly.mediaroom.com/2020-01-29-Lilly-Receives-FDA-Priority-Review-for-the-Selpercatinib-New-Drug-Application\n",
      "http://lilly.mediaroom.com/2020-01-28-Lilly-plans-donation-of-200-000-insulin-KwikPens-over-next-three-years-to-support-lower-income-communities\n",
      "http://lilly.mediaroom.com/2020-01-27-US-FDA-approves-only-triple-combination-tablet-with-Jardiance-R-for-adults-with-type-2-diabetes\n",
      "http://lilly.mediaroom.com/2020-01-27-Lilly-and-Incyte-Announce-Top-Line-Results-from-Phase-3-Study-BREEZE-AD4-of-Oral-Selective-JAK-Inhibitor-Baricitinib-in-Combination-with-Topical-Corticosteroids-in-Patients-with-Moderate-to-Severe-Atopic-Dermatitis-Not-Controlled-with-Cyclospor\n",
      "http://lilly.mediaroom.com/2020-01-24-Anat-Hakim-to-join-Lilly-as-General-Counsel\n",
      "http://lilly.mediaroom.com/2020-01-21-Governor-Cooper-Announces-over-460-Jobs-in-Durham-as-Eli-Lilly-and-Company-Selects-North-Carolina-for-Major-Pharmaceutical-Plant\n",
      "http://lilly.mediaroom.com/2020-01-16-Lilly-Confirms-Date-and-Conference-Call-for-Fourth-Quarter-2019-Financial-Results-Announcement\n",
      "http://lilly.mediaroom.com/2020-01-15-Lilly-Anna-Kaiser-Launch-30-Day-Thriver-Challenge-to-Increase-Awareness-of-Daily-Stress-of-Living-with-Metastatic-Breast-Cancer-Elevate-Support-for-Women-and-Men-Living-with-the-Disease\n",
      "http://lilly.mediaroom.com/2020-01-14-Lilly-expands-insulin-affordability-options-with-lower-priced-versions-of-Humalog-R-Mix75-25-TM-KwikPen-R-and-Humalog-R-Junior-KwikPen-R\n",
      "http://lilly.mediaroom.com/2020-01-13-Tyvyt-R-Sintilimab-Injection-Combined-with-ALIMTA-R-Pemetrexed-and-Platinum-Met-Predefined-Primary-Endpoint-in-Phase-3-ORIENT-11-Study-as-First-Line-Therapy-in-Nonsquamous-NSCLC\n",
      "http://lilly.mediaroom.com/2020-01-10-Lilly-Announces-Agreement-to-Acquire-Dermira\n",
      "http://lilly.mediaroom.com/2020-01-09-Eli-Lilly-and-Company-in-Collaboration-with-Strateos-Inc-Launch-Remote-Controlled-Robotic-Cloud-Lab\n",
      "http://lilly.mediaroom.com/2020-01-02-Lilly-to-Participate-in-J-P-Morgan-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2019-12-30-U-S-District-Court-Rules-in-Favor-of-Lilly-in-Alimta-Vitamin-Regimen-Patent-Lawsuit\n",
      "http://lilly.mediaroom.com/2019-12-30-Lilly-Opens-Phase-3-Clinical-Trial-in-RET-Mutant-Medullary-Thyroid-Cancer\n",
      "http://lilly.mediaroom.com/2019-12-19-Lilly-Launches-Campaign-to-Increase-Awareness-of-Insulin-Cost-Saving-Options\n",
      "http://lilly.mediaroom.com/2019-12-18-Lilly-Announces-the-Launch-of-TRIUMPH-the-First-Long-Term-Real-World-Evidence-Study-of-Emgality-R-galcanezumab-gnlm\n",
      "http://lilly.mediaroom.com/2019-12-17-Lilly-Announces-2020-Financial-Guidance-Updates-2019-Guidance\n",
      "http://lilly.mediaroom.com/2019-12-16-Lilly-Announces-15-Percent-Dividend-Increase\n",
      "http://lilly.mediaroom.com/2019-12-16-Lilly-to-Integrate-Dexcom-CGM-into-Personalized-Diabetes-Management-System\n",
      "http://lilly.mediaroom.com/2019-12-13-Boehringer-Ingelheim-and-Lilly-provide-update-on-Jardiance-R-phase-III-exercise-ability-studies-in-chronic-heart-failure\n",
      "http://lilly.mediaroom.com/2019-12-13-CHMP-Issues-Positive-Opinion-to-Expand-CYRAMZA-R-ramucirumab-Label-to-Include-Results-from-RELAY-Study-in-Patients-with-Metastatic-EGFR-Mutated-Non-Small-Cell-Lung-Cancer\n",
      "http://lilly.mediaroom.com/2019-12-11-Lilly-Opens-First-Ever-Randomized-Phase-3-Clinical-Trial-in-Treatment-Naive-RET-Fusion-Positive-Non-Small-Cell-Lung-Cancer\n",
      "http://lilly.mediaroom.com/2019-12-08-Lilly-Presents-Interim-Clinical-Data-from-LOXO-305-Dose-Escalation-Trial-in-B-Cell-Leukemias-and-Lymphomas-at-the-American-Society-Hematology-Annual-Meeting\n",
      "http://lilly.mediaroom.com/2019-12-05-Lilly-Announces-New-Leadership-and-Strategy-in-Oncology-Research-and-Development\n",
      "http://lilly.mediaroom.com/2019-12-02-Lilly-to-Participate-in-Evercore-ISI-2nd-Annual-HealthCONx-Conference\n",
      "http://lilly.mediaroom.com/2019-12-02-Eli-Lilly-and-Company-Unveils-Shared-Innovation-Laboratory-in-South-San-Francisco\n",
      "http://lilly.mediaroom.com/2019-12-02-Lilly-Names-HealthVoyager-as-Winner-of-Digital-Health-Innovation-Challenge-for-Inflammatory-Bowel-Disease-IBD\n",
      "http://lilly.mediaroom.com/2019-11-20-Lilly-announces-400-million-capital-investment-in-manufacturing-facilities-in-Indianapolis\n",
      "http://lilly.mediaroom.com/2019-11-19-Lilly-Confirms-Date-and-Conference-Call-for-2020-Financial-Guidance-Announcement\n",
      "http://lilly.mediaroom.com/2019-11-17-Interim-analysis-from-EMPRISE-real-world-study-shows-Jardiance-R-decreased-risk-of-hospitalization-for-heart-failure-compared-with-DPP-4-inhibitors-and-GLP-1-receptor-agonists\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "http://lilly.mediaroom.com/2019-11-13-Boehringer-Ingelheim-and-Lilly-announce-outcome-of-FDA-Advisory-Committee-meeting-for-empagliflozin-2-5-mg-as-adjunct-to-insulin-for-adults-with-type-1-diabetes\n",
      "http://lilly.mediaroom.com/2019-11-12-Boehringer-Ingelheim-and-Lilly-initiate-first-ever-study-to-assess-Jardiance-R-in-people-hospitalized-for-acute-heart-failure-who-have-been-stabilized\n",
      "http://lilly.mediaroom.com/2019-11-12-ACR-2019-Lilly-Presents-52-Week-Head-to-Head-SPIRIT-H2H-Data-from-Taltz-R-ixekizumab-Versus-Humira-R-adalimumab-Trial-in-Psoriatic-Arthritis\n",
      "http://lilly.mediaroom.com/2019-11-12-ACR-2019-Lilly-Presents-Positive-New-Data-from-COAST-X-a-Phase-3-Study-of-Taltz-R-ixekizumab-in-Patients-with-Non-Radiographic-Axial-Spondyloarthritis\n",
      "http://lilly.mediaroom.com/2019-11-08-Lilly-Reinforces-its-Commitment-to-Rheumatology-through-Data-Showcased-at-the-ACR-ARP-Annual-Meeting\n",
      "http://lilly.mediaroom.com/2019-11-07-Lilly-Announces-the-Pricing-Terms-of-its-Cash-Tender-Offer-for-Up-to-2-000-006-000-Aggregate-Principal-Amount-of-Its-Outstanding-Debt-Securities\n",
      "http://lilly.mediaroom.com/2019-11-07-Lilly-Announces-the-Early-Tender-Results-and-Upsizing-of-Its-Pending-Cash-Tender-Offer-to-Up-to-2-000-006-000-Aggregate-Principal-Amount-of-Its-Outstanding-Debt-Securities\n",
      "http://lilly.mediaroom.com/2019-11-06-Eli-Lilly-and-Company-to-Present-Multiple-Abstracts-for-LOXO-305-at-ASH-2019\n",
      "http://lilly.mediaroom.com/2019-11-04-Lilly-to-Participate-in-Credit-Suisse-28th-Annual-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2019-11-04-Boehringer-Ingelheim-and-Lilly-modernise-alliance-to-focus-full-expertise-on-Jardiance-R\n",
      "http://lilly.mediaroom.com/2019-10-24-Lilly-Announces-Cash-Tender-Offer-for-Up-to-2-0-Billion-Aggregate-Principal-Amount-of-Its-Outstanding-Debt-Securities\n",
      "http://lilly.mediaroom.com/2019-10-23-Lilly-Reports-Strong-Third-Quarter-2019-Financial-Results-Raises-2019-EPS-Guidance\n",
      "http://lilly.mediaroom.com/2019-10-23-Enrique-Conterno-Senior-Vice-President-and-President-of-Lilly-Diabetes-and-Lilly-USA-to-Retire-at-End-of-Year-Mike-Mason-to-Succeed-Conterno\n",
      "http://lilly.mediaroom.com/2019-10-21-Lilly-Declares-Fourth-Quarter-2019-Dividend\n",
      "http://lilly.mediaroom.com/2019-10-16-Lilly-Announces-Phase-3-Study-in-Patients-with-Metastatic-Pancreatic-Cancer-Did-Not-Meet-Primary-Endpoint-of-Overall-Survival\n",
      "http://lilly.mediaroom.com/2019-10-12-Lilly-Presents-Positive-Results-for-Taltz-R-ixekizumab-in-Pediatric-Patients-with-Moderate-to-Severe-Plaque-Psoriasis-at-the-28th-Annual-European-Academy-of-Dermatology-and-Venereology-EADV-Congress\n",
      "http://lilly.mediaroom.com/2019-10-11-Lillys-REYVOW-TM-lasmiditan-The-First-and-Only-Medicine-in-a-New-Class-of-Acute-Treatment-for-Migraine-Receives-FDA-Approval\n",
      "http://lilly.mediaroom.com/2019-10-08-Lilly-to-Unveil-New-Data-for-the-Treatments-of-Complex-Dermatological-Conditions-at-the-28th-Annual-European-Academy-of-Dermatology-and-Venereology-EADV-Congress\n",
      "http://lilly.mediaroom.com/2019-10-07-Lillys-CYRAMZA-R-ramucirumab-Phase-3-Data-in-First-Line-EGFR-Mutated-Non-Small-Cell-Lung-Cancer-Published-in-The-Lancet-Oncology\n",
      "http://lilly.mediaroom.com/2019-10-03-Lilly-Announces-Voluntary-Delisting-from-Euronext-Paris\n",
      "http://lilly.mediaroom.com/2019-10-03-New-Head-to-Head-Data-Show-Taltz-R-ixekizumab-Superiority-versus-TREMFYA-R-guselkumab-in-People-with-Moderate-to-Severe-Plaque-Psoriasis\n",
      "http://lilly.mediaroom.com/2019-10-02-Lilly-Confirms-Date-and-Conference-Call-for-Third-Quarter-2019-Financial-Results-Announcement\n",
      "http://lilly.mediaroom.com/2019-09-29-Lilly-Announces-Positive-Registrational-Data-for-Selpercatinib-LOXO-292-in-Heavily-Pretreated-RET-Altered-Thyroid-Cancers\n",
      "http://lilly.mediaroom.com/2019-09-23-Lilly-Oncology-to-Present-Robust-Data-across-Its-Growing-Portfolio-at-ESMO-2019\n",
      "http://lilly.mediaroom.com/2019-09-20-CHMP-Issues-Positive-Opinion-to-Expand-Trulicity-R-dulaglutide-Label-to-Include-Results-from-REWIND-Cardiovascular-Outcomes-Trial\n",
      "http://lilly.mediaroom.com/2019-09-19-Lilly-Announces-Webcast-to-Discuss-ESMO-2019-Presentations\n",
      "http://lilly.mediaroom.com/2019-09-09-Lilly-Announces-Positive-Results-for-Selpercatinib-LOXO-292-Demonstrating-a-68-Percent-Objective-Response-Rate-and-Sustained-Durability-in-Heavily-Pretreated-RET-Fusion-Positive-Non-Small-Cell-Lung-Cancer\n",
      "http://lilly.mediaroom.com/2019-09-05-Lillys-Pain-Clinical-Trial-Protocol-Selected-for-FDA-Complex-Innovative-Trial-Designs-Pilot-Meeting-Program\n",
      "http://lilly.mediaroom.com/2019-09-04-Lilly-to-Participate-in-Morgan-Stanley-Global-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2019-08-26-Lilly-Receives-U-S-FDA-Approval-for-Taltz-R-ixekizumab-for-the-Treatment-of-Active-Ankylosing-Spondylitis-Radiographic-Axial-Spondyloarthritis\n",
      "http://lilly.mediaroom.com/2019-08-23-Lilly-Announces-Top-Line-Phase-3-Results-for-Oral-JAK-Inhibitor-Baricitinib-in-Combination-with-Topical-Corticosteroids-in-Adult-Patients-with-Moderate-to-Severe-Atopic-Dermatitis\n",
      "http://lilly.mediaroom.com/2019-08-22-Arbitration-panel-rules-in-favor-of-Lilly-in-complaint-filed-by-Adocia\n",
      "http://lilly.mediaroom.com/2019-08-19-Lilly-Announces-Webcast-to-Discuss-World-Conference-on-Lung-Cancer-Presentation\n",
      "http://lilly.mediaroom.com/2019-08-14-Lilly-Launches-Open-Innovation-Challenge-to-Help-Transform-Inflammatory-Bowel-Disease-IBD-Care-through-Digital-Health\n",
      "http://lilly.mediaroom.com/2019-08-13-Lilly-Announces-Superiority-of-Taltz-R-ixekizumab-versus-TREMFYA-R-guselkumab-in-Delivering-Total-Skin-Clearance-at-Week-12-in-Topline-Results-from-Head-to-Head-IXORA-R-Trial-in-People-Living-with-Moderate-to-Severe-Plaque-Psoriasis\n",
      "http://lilly.mediaroom.com/2019-08-09-U-S-Court-of-Appeals-Rules-in-Favor-of-Lilly-in-Alimta-Alternate-Salt-Form-Patent-Lawsuit\n",
      "http://lilly.mediaroom.com/2019-08-08-Lilly-Evidation-Health-and-Apple-Study-Shows-Personal-Digital-Devices-May-Help-in-the-Identification-of-Mild-Cognitive-Impairment-and-Mild-Alzheimers-Disease-Dementia\n",
      "http://lilly.mediaroom.com/2019-08-07-Lilly-Announces-Leadership-Changes-in-Corporate-Business-Development-Oncology-R-D-and-Managed-Healthcare-Services\n",
      "http://lilly.mediaroom.com/2019-08-05-Lilly-Announces-Positive-Results-for-Emgality-R-galcanezumab-gnlm-from-the-CONQUER-Study-in-Patients-who-Failed-Previous-Migraine-Preventive-Treatments\n",
      "http://lilly.mediaroom.com/2019-07-30-Lilly-Reports-Second-Quarter-2019-Financial-Results-Raises-2019-EPS-Guidance\n",
      "http://lilly.mediaroom.com/2019-07-30-Lillys-Verzenio-R-abemaciclib-Significantly-Extended-Life-in-Women-with-HR-HER2-Advanced-Breast-Cancer-in-MONARCH-2\n",
      "http://lilly.mediaroom.com/2019-07-24-BAQSIMI-TM-glucagon-Nasal-Powder-3-mg-the-First-and-Only-Nasally-Administered-Glucagon-to-Treat-Severe-Hypoglycemia-in-Adults-and-Children-with-Diabetes-Ages-Four-Years-and-Older-Approved-by-FDA\n",
      "http://lilly.mediaroom.com/2019-07-13-Lilly-Presents-New-Findings-on-Stigma-Faced-by-People-with-Migraine-Based-on-Interim-Results-from-the-OVERCOME-Observational-Study\n",
      "http://lilly.mediaroom.com/2019-07-12-Lillys-OVERCOME-Observational-Study-Reveals-Inconsistent-and-Sub-Optimal-Treatment-Landscape-for-Migraine\n",
      "http://lilly.mediaroom.com/2019-07-12-AHS-2019-Post-Hoc-Analyses-of-Phase-3-Pivotal-Studies-of-Emgality-R-galcanezumab-gnlm-Show-Improvements-in-Daily-Functioning-and-Reductions-in-Disability-in-Patients-with-Chronic-and-Episodic-Migraine\n",
      "http://lilly.mediaroom.com/2019-07-11-Lilly-Announces-Changes-in-Senior-Leadership\n",
      "http://lilly.mediaroom.com/2019-07-11-New-England-Journal-of-Medicine-Publishes-Positive-Phase-3-Data-for-Emgality-R-galcanezumab-gnlm-in-Episodic-Cluster-Headache\n",
      "http://lilly.mediaroom.com/2019-07-10-Lilly-Announces-Upcoming-Presentation-of-New-Data-Indicating-Rise-in-Opioid-Use-for-Migraine-Treatment\n",
      "http://lilly.mediaroom.com/2019-07-09-Lilly-Confirms-Date-and-Conference-Call-for-Second-Quarter-2019-Financial-Results-Announcement\n",
      "http://lilly.mediaroom.com/2019-06-26-Lillys-AWARD-11-trial-studying-higher-investigational-doses-of-Trulicity-R-dulaglutide-demonstrated-superiority-in-A1C-reduction-in-people-with-type-2-diabetes\n",
      "http://lilly.mediaroom.com/2019-06-26-U-S-FDA-Grants-Fast-Track-Designation-to-Empagliflozin-for-the-Treatment-of-Chronic-Heart-Failure\n",
      "http://lilly.mediaroom.com/2019-06-19-Lilly-Declares-Third-Quarter-2019-Dividend\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "http://lilly.mediaroom.com/2019-06-14-Lilly-Presents-Positive-Results-for-Taltz-R-ixekizumab-vs-Humira-R-adalimumab-in-a-Head-to-Head-SPIRIT-H2H-Superiority-Study-in-Patients-with-Active-Psoriatic-Arthritis-at-the-European-Congress-of-Rheumatology\n",
      "http://lilly.mediaroom.com/2019-06-11-Lilly-to-Present-5-Year-Sustained-Efficacy-and-Safety-Results-for-Taltz-R-ixekizumab-in-Patients-with-Plaque-Psoriasis-at-the-World-Congress-of-Dermatology\n",
      "http://lilly.mediaroom.com/2019-06-10-Detailed-findings-from-CAROLINA-R-outcome-trial-support-long-term-cardiovascular-safety-profile-of-Tradjenta-R\n",
      "http://lilly.mediaroom.com/2019-06-10-New-analysis-shows-cardiorenal-risk-reductions-of-Jardiance-R-are-consistent-in-adults-with-type-2-diabetes-cardiovascular-disease-and-kidney-disease-without-overt-proteinuria\n",
      "http://lilly.mediaroom.com/2019-06-09-Trulicity-R-dulaglutide-significantly-reduced-major-cardiovascular-events-for-broad-range-of-people-with-type-2-diabetes\n",
      "http://lilly.mediaroom.com/2019-06-09-Lillys-ultra-rapid-lispro-provided-similar-A1C-reductions-compared-to-Humalog-R-insulin-lispro-with-superior-post-meal-blood-glucose-reductions\n",
      "http://lilly.mediaroom.com/2019-06-08-Lillys-tirzepatide-demonstrates-benefits-in-data-presented-at-the-American-Diabetes-Associations-R-79-Scientific-Sessions-R\n",
      "http://lilly.mediaroom.com/2019-06-06-Lilly-to-Present-New-Data-and-Commitment-to-Patient-Centered-Solutions-at-the-Annual-European-Congress-of-Rheumatology\n",
      "http://lilly.mediaroom.com/2019-06-05-Lilly-to-Showcase-Scientific-Innovation-within-Dermatology-Portfolio-at-24th-World-Congress-of-Dermatology\n",
      "http://lilly.mediaroom.com/2019-06-04-FDA-Approves-Emgality-R-galcanezumab-gnlm-as-the-First-and-Only-Medication-for-the-Treatment-of-Episodic-Cluster-Headache-that-Reduces-the-Frequency-of-Attacks\n",
      "http://lilly.mediaroom.com/2019-06-04-U-S-FDA-Accepts-New-Drug-Application-for-Triple-Combination-Tablet-for-Adults-with-Type-2-Diabetes\n",
      "http://lilly.mediaroom.com/2019-05-31-Hurricane-Season-is-Almost-Here-Are-You-Ready\n",
      "http://lilly.mediaroom.com/2019-05-30-Lilly-to-Participate-in-Goldman-Sachs-Global-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2019-05-29-Lilly-Announces-Webcast-to-Discuss-ADA-Presentations-and-Diabetes-Portfolio\n",
      "http://lilly.mediaroom.com/2019-05-28-Lilly-Announces-Licensing-Agreement-for-Non-Opioid-Pain-Asset-from-Centrexion-Therapeutics\n",
      "http://lilly.mediaroom.com/2019-05-22-Lillys-Lower-Priced-Insulin-Now-Available\n",
      "http://lilly.mediaroom.com/2019-05-21-Lillys-Mirikizumab-Met-Primary-Endpoint-and-Key-Secondary-Endpoints-in-Phase-2-Study-Including-Reductions-of-Gastrointestinal-Lesions\n",
      "http://lilly.mediaroom.com/2019-05-16-Lilly-to-Participate-in-UBS-Global-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2019-05-15-Data-Presentations-at-ASCO-2019-Highlight-Lillys-Targeted-Approach-to-Developing-Treatments-for-Patients-Living-with-Cancer\n",
      "http://lilly.mediaroom.com/2019-05-15-Lilly-to-Participate-in-Bank-of-America-Merrill-Lynch-Health-Care-Conference\n",
      "http://lilly.mediaroom.com/2019-05-13-Lillys-CYRAMZA-R-ramucirumab-Becomes-First-FDA-Approved-Biomarker-Driven-Therapy-in-Patients-with-Hepatocellular-Carcinoma\n",
      "http://lilly.mediaroom.com/2019-05-08-AAN-2019-Two-New-Analyses-of-Lasmiditan-Phase-3-Studies-Measured-Onset-of-Effect-and-the-Effect-of-Lasmiditan-in-Patients-with-Prior-Triptan-Experience\n",
      "http://lilly.mediaroom.com/2019-05-06-Lilly-Declares-Second-Quarter-2019-Dividend\n",
      "http://lilly.mediaroom.com/2019-05-06-AAN-2019-Pooled-Analyses-of-Two-Emgality-R-galcanezumab-gnlm-Phase-3-Studies-Show-Reduction-in-Monthly-Migraine-Headache-Days-in-Low-and-High-Frequency-Episodic-Migraine-Subgroups\n",
      "http://lilly.mediaroom.com/2019-05-02-Lilly-to-Present-New-Data-at-AAN-2019-on-Emgality-R-galcanezumab-gnlm-and-Lasmiditan-Reinforcing-Breadth-of-Headache-Disorders-Portfolio\n",
      "http://lilly.mediaroom.com/2019-04-30-Lilly-Reports-Solid-First-Quarter-2019-Financial-Results-Updates-2019-Guidance-to-Reflect-Disposition-of-Elanco-Animal-Health\n",
      "http://lilly.mediaroom.com/2019-04-26-U-S-Court-of-Appeals-Rules-in-Favor-of-Lilly-in-Alimta-Vitamin-Regimen-Patent-Lawsuit\n",
      "http://lilly.mediaroom.com/2019-04-25-Lilly-to-Establish-an-Access-Program-for-Patients-as-it-Prepares-to-Withdraw-Lartruvo-from-the-Global-Market\n",
      "http://lilly.mediaroom.com/2019-04-22-Lilly-Announces-Sale-of-Legacy-Antibiotics-Brands-and-Manufacturing-Facility-in-China\n",
      "http://lilly.mediaroom.com/2019-04-22-Lilly-Announces-Positive-Top-Line-Results-for-COAST-X-a-52-Week-Placebo-Controlled-Study-of-Taltz-R-ixekizumab-in-Patients-with-Non-Radiographic-Axial-Spondyloarthritis\n",
      "http://lilly.mediaroom.com/2019-04-22-Lilly-and-Avidity-Biosciences-Announce-Licensing-and-Research-Collaboration\n",
      "http://lilly.mediaroom.com/2019-04-18-Pfizer-and-Lilly-Announce-Top-Line-Results-from-Long-Term-Phase-3-Study-of-Tanezumab-in-Patients-with-Osteoarthritis\n",
      "http://lilly.mediaroom.com/2019-03-26-Lilly-and-ImmuNext-Announce-Licensing-and-Research-Collaboration\n",
      "http://lilly.mediaroom.com/2019-03-21-Survey-Reveals-Genital-Psoriasis-May-Reduce-Patients-Self-Confidence-and-Hinder-Them-from-Having-Close-Relationships\n",
      "http://lilly.mediaroom.com/2019-03-20-NCCN-Announces-Six-Quality-Improvement-Projects-in-Gastric-Cancer-Care-Approved-for-Collaboration-with-Lilly-Oncology\n",
      "http://lilly.mediaroom.com/2019-03-13-Lilly-Announces-Final-Results-of-Elanco-Exchange-Offer\n",
      "http://lilly.mediaroom.com/2019-03-12-Lillys-CYRAMZA-R-ramucirumab-Phase-3-RELAY-Trial-Met-Primary-Endpoint-Significantly-Improving-Progression-Free-Survival-in-First-Line-Treatment-of-Patients-with-Metastatic-EGFR-Mutated-Non-Small-Cell-Lung-Cancer\n",
      "http://lilly.mediaroom.com/2019-03-11-Lilly-Announces-Preliminary-Results-of-Elanco-Exchange-Offer\n",
      "http://lilly.mediaroom.com/2019-03-08-Lilly-to-Participate-in-Barclays-Global-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2019-03-07-Lilly-to-Participate-in-Cowen-Health-Care-Conference\n",
      "http://lilly.mediaroom.com/2019-03-07-Lilly-Announces-Final-Exchange-Ratio-of-4-5121-for-Elanco-Exchange-Offer\n",
      "http://lilly.mediaroom.com/2019-03-05-Lilly-Receives-FDA-Priority-Review-Designation-for-Emgality-R-galcanezumab-gnlm-Injection-for-the-Preventive-Treatment-of-Episodic-Cluster-Headache-in-Adults\n",
      "http://lilly.mediaroom.com/2019-03-04-Lilly-to-Introduce-Lower-Priced-Insulin\n",
      "http://lilly.mediaroom.com/2019-03-01-Lilly-to-Present-Data-Demonstrating-Continued-Scientific-Advancements-in-Broad-Dermatology-Portfolio-at-AAD-Annual-Meeting\n",
      "http://lilly.mediaroom.com/2019-02-19-Pfizer-and-Lilly-Announce-Top-line-Results-From-Phase-3-Study-of-Tanezumab-in-Chronic-Low-Back-Pain\n",
      "http://lilly.mediaroom.com/2019-02-15-Lilly-Completes-Acquisition-of-Loxo-Oncology\n",
      "http://lilly.mediaroom.com/2019-02-14-Lilly-To-Participate-in-Leerink-Partners-Global-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2019-02-14-Boehringer-Ingelheim-and-Lilly-announce-the-CAROLINA-R-cardiovascular-outcome-trial-of-Tradjenta-R-met-its-primary-endpoint-of-non-inferiority-compared-with-glimepiride\n",
      "http://lilly.mediaroom.com/2019-02-08-Lilly-to-Participate-in-Guggenheim-Healthcare-Talks-Idea-Forum\n",
      "http://lilly.mediaroom.com/2019-02-08-Lilly-Will-Initiate-Divestiture-of-its-Remaining-Interest-in-Elanco-Animal-Health\n",
      "http://lilly.mediaroom.com/2019-02-06-Lilly-Reports-Strong-Fourth-Quarter-and-Full-Year-2018-Financial-Results-Lowers-2019-EPS-Guidance-to-Reflect-the-Pending-Acquisition-of-Loxo-Oncology\n",
      "http://lilly.mediaroom.com/2019-02-04-Lilly-Announces-Top-Line-Phase-3-Results-for-Baricitinib-in-Patients-with-Moderate-to-Severe-Atopic-Dermatitis\n",
      "http://lilly.mediaroom.com/2019-02-01-Lilly-and-Loxo-Oncology-Announce-Expiration-of-HSR-Act-Waiting-Period-in-Connection-with-Proposed-Transaction\n",
      "http://lilly.mediaroom.com/2019-01-31-FDA-Expands-Lillys-ALIMTA-R-pemetrexed-Label-with-Combination-of-KEYTRUDA-R-pembrolizumab-and-Platinum-Chemotherapy-for-the-First-Line-Treatment-of-Metastatic-Nonsquamous-Non-Small-Cell-Lung-Cancer\n",
      "http://lilly.mediaroom.com/2019-01-30-Lilly-Revises-Date-for-Fourth-Quarter-2018-Financial-Results-Announcement\n",
      "http://lilly.mediaroom.com/2019-01-29-Pfizer-and-Lilly-Announce-Top-Line-Results-From-Second-Phase-3-Study-of-Tanezumab-in-Osteoarthritis-Pain\n",
      "http://lilly.mediaroom.com/2019-01-23-Government-Employees-Affected-by-Federal-Shutdown-Encouraged-to-Contact-Lilly-Diabetes-Solution-Center-to-Access-Insulin\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "http://lilly.mediaroom.com/2019-01-21-Lilly-Confirms-Date-and-Conference-Call-for-Fourth-Quarter-2018-Financial-Results-Announcement\n",
      "http://lilly.mediaroom.com/2019-01-18-Lilly-Phase-3-REACH-2-Trial-Data-Published-in-The-Lancet-Oncology-Shows-Improvement-in-Overall-Survival-with-CYRAMZA-R-ramucirumab-in-Second-Line-AFP-High-Hepatocellular-Carcinoma-Patients\n",
      "http://lilly.mediaroom.com/2019-01-18-Lilly-Reports-Results-of-Phase-3-Soft-Tissue-Sarcoma-Study-of-LARTRUVO-R\n",
      "http://lilly.mediaroom.com/2019-01-07-Lilly-Announces-Agreement-To-Acquire-Loxo-Oncology\n",
      "http://lilly.mediaroom.com/2019-01-03-Lilly-to-Participate-in-J-P-Morgan-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2018-12-19-Lilly-Announces-Financial-Guidance-Reviews-Commercial-Performance-and-Highlights-Promising-Pipeline-Opportunities-at-Investment-Community-Meeting\n",
      "http://lilly.mediaroom.com/2018-12-19-Lilly-Announces-15-Percent-Dividend-Increase\n",
      "http://lilly.mediaroom.com/2018-12-18-Lilly-and-Aduro-Biotech-Announce-Research-Collaboration-and-License-Agreement-to-Develop-Novel-Immunotherapies\n",
      "http://lilly.mediaroom.com/2018-12-18-Lilly-announces-publication-of-analyses-showing-benefit-of-the-addition-of-Verzenio-R-abemaciclib-in-multiple-subgroups-of-patients-with-advanced-breast-cancer-identified-as-having-a-more-concerning-prognosis\n",
      "http://lilly.mediaroom.com/2018-12-17-Lilly-Announces-Positive-Top-Line-Results-for-Taltz-R-ixekizumab-vs-Humira-R-adalimumab-in-a-Head-to-Head-SPIRIT-H2H-Superiority-Study-in-Patients-with-Active-Psoriatic-Arthritis\n",
      "http://lilly.mediaroom.com/2018-12-14-Lilly-to-Acquire-Pre-Clinical-Pain-Program-from-Hydra-Biosciences\n",
      "http://lilly.mediaroom.com/2018-12-14-Lilly-and-Evidation-Health-Expand-Collaboration-to-Analyze-Data-from-Smartphones-and-Connected-Sensors\n",
      "http://lilly.mediaroom.com/2018-12-13-FDA-Grants-Fast-Track-Designation-to-the-Baricitinib-Development-Program-for-the-Treatment-of-Systemic-Lupus-Erythematosus-SLE\n",
      "http://lilly.mediaroom.com/2018-12-13-Boehringer-Ingelheim-and-Lilly-Partner-with-Duke-Clinical-Research-Institute-to-Advance-Multidisciplinary-Care-for-People-with-Type-2-Diabetes-and-Cardiovascular-Disease\n",
      "http://lilly.mediaroom.com/2018-12-12-Lilly-and-AC-Immune-Announce-License-and-Collaboration-Agreement\n",
      "http://lilly.mediaroom.com/2018-12-03-NCCN-Oncology-Research-Program-Awarded-2-Million-from-Lilly-to-Study-Mechanisms-of-Resistance-to-CDK4-6-Inhibitors-in-Breast-Cancer-Treatment\n",
      "http://lilly.mediaroom.com/2018-11-29-Lilly-to-Present-Clinical-Data-for-Verzenio-R-abemaciclib-and-Real-World-Evidence-across-HR-HER2-Metastatic-Breast-Cancer-at-2018-SABCS\n",
      "http://lilly.mediaroom.com/2018-11-27-Lilly-to-Announce-2019-Financial-Guidance-Highlight-Late-Stage-Pipeline-Opportunities-and-Discuss-Commercial-Performance-at-Upcoming-Investment-Community-Meeting\n",
      "http://lilly.mediaroom.com/2018-11-26-Jardiance-R-Recommended-as-Preferred-SGLT2-Inhibitor-for-Adults-with-Type-2-Diabetes-and-Established-Cardiovascular-Disease-in-American-College-of-Cardiology-Expert-Consensus-Decision-Pathway\n",
      "http://lilly.mediaroom.com/2018-11-14-Lilly-Submits-New-Drug-Application-to-the-FDA-for-Lasmiditan-for-Acute-Treatment-of-Migraine-Receives-Breakthrough-Therapy-Designation-for-Emgality-TM-galcanezumab-gnlm-for-Prevention-of-Episodic-Cluster-Headache\n",
      "http://lilly.mediaroom.com/2018-11-08-Lilly-to-Participate-in-Credit-Suisse-27th-Annual-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2018-11-06-Lilly-Delivers-Solid-Third-Quarter-2018-Results-Revises-EPS-Guidance\n",
      "http://lilly.mediaroom.com/2018-11-05-Lilly-and-NextCure-Announce-Collaboration-to-Discover-and-Develop-Novel-Immuno-Oncology-Medicines\n",
      "http://lilly.mediaroom.com/2018-11-05-Trulicity-R-dulaglutide-demonstrates-superiority-in-reduction-of-cardiovascular-events-for-broad-range-of-people-with-type-2-diabetes\n",
      "http://lilly.mediaroom.com/2018-11-05-Initial-results-from-EMPRISE-real-world-evidence-study-show-Jardiance-R-was-associated-with-reduced-risk-for-hospitalization-for-heart-failure-compared-with-DPP-4-inhibitors-in-people-with-type-2-diabetes-with-and-without-cardiovascular-disease\n",
      "http://lilly.mediaroom.com/2018-10-29-Lilly-and-Dicerna-Announce-RNAi-Licensing-and-Research-Collaboration\n",
      "http://lilly.mediaroom.com/2018-10-23-Complete-Results-from-First-Study-in-Ongoing-Phase-3-Program-for-Tanezumab-Demonstrated-Significant-Improvement-in-Pain-and-Function-in-Osteoarthritis-Patients\n",
      "http://lilly.mediaroom.com/2018-10-22-ACR-2018-Lilly-Announces-Positive-Results-for-Two-Phase-3-Studies-of-Taltz-R-ixekizumab-in-Ankylosing-Spondylitis-Radiographic-Axial-Spondyloarthritis\n",
      "http://lilly.mediaroom.com/2018-10-21-ACR-2018-Lilly-Shares-Updated-Safety-Analysis-of-OLUMIANT-R-baricitinib-in-Patients-with-Moderately-to-Severely-Active-Rheumatoid-Arthritis\n",
      "http://lilly.mediaroom.com/2018-10-16-Karen-Walker-Elected-to-Lilly-Board-of-Directors\n",
      "http://lilly.mediaroom.com/2018-10-15-Lilly-Declares-Fourth-Quarter-2018-Dividend\n",
      "http://lilly.mediaroom.com/2018-10-15-New-Data-Showcasing-Lillys-Growing-Commitment-in-Rheumatology-to-be-Featured-at-the-ACR-ARHP-Annual-Meeting\n",
      "http://lilly.mediaroom.com/2018-10-12-Lilly-and-Metastatic-Breast-Cancer-Advocates-Launch-Thriver-Movement-to-Elevate-Understanding-of-the-Daily-Impact-of-the-Disease-Encourage-Public-to-do-More-for-MBC\n",
      "http://lilly.mediaroom.com/2018-10-10-New-analysis-estimates-the-positive-impact-of-Jardiance-R-on-life-expectancy-in-adults-with-type-2-diabetes-and-established-cardiovascular-disease\n",
      "http://lilly.mediaroom.com/2018-10-08-Lilly-to-Present-New-Data-From-Oncology-Portfolio-at-ESMO-2018-Congress-Showcasing-Patient-Centric-Advances-in-Cancer-Care\n",
      "http://lilly.mediaroom.com/2018-10-04-Boehringer-Ingelheim-and-Lilly-present-full-results-of-Tradjenta-R-s-CARMELINA-R-cardiovascular-outcome-trial\n",
      "http://lilly.mediaroom.com/2018-10-04-Boehringer-Ingelheim-and-Lilly-present-full-results-from-EASE-Phase-III-program-for-empagliflozin-as-adjunct-to-insulin-in-type-1-diabetes\n",
      "http://lilly.mediaroom.com/2018-10-04-Lillys-Investigational-Dual-GIP-and-GLP-1-Receptor-Agonist-Shows-Significant-Reduction-in-HbA1c-and-Body-Weight-in-People-With-Type-2-Diabetes\n",
      "http://lilly.mediaroom.com/2018-10-03-Lilly-Confirms-Date-and-Conference-Call-for-Third-Quarter-2018-Financial-Results-Announcement\n",
      "http://lilly.mediaroom.com/2018-10-02-Results-from-Two-Phase-3-Studies-Show-Lillys-Ultra-Rapid-Lispro-URLi-Met-Primary-Efficacy-Endpoint-in-People-with-Type-1-and-Type-2-Diabetes\n",
      "http://lilly.mediaroom.com/2018-09-27-Lillys-Emgality-TM-galcanezumab-gnlm-Receives-U-S-FDA-Approval-for-the-Preventive-Treatment-of-Migraine-in-Adults\n",
      "http://lilly.mediaroom.com/2018-09-26-Chugai-and-Lilly-Enter-into-a-License-Agreement-for-Oral-GLP-1-Agonist-OWL833\n",
      "http://lilly.mediaroom.com/2018-09-21-Lilly-Receives-Positive-CHMP-Opinion-for-Emgality-TM-galcanezumab-for-the-Prophylaxis-of-Migraine-in-Adults\n",
      "http://lilly.mediaroom.com/2018-09-13-New-Lilly-Diabetes-Center-of-Excellence-Established-at-the-Indiana-Bioscience-Research-Institute\n",
      "http://lilly.mediaroom.com/2018-09-12-NCCN-and-Lilly-Support-Quality-Improvements-for-Gastric-Cancer-Care\n",
      "http://lilly.mediaroom.com/2018-09-10-Lilly-to-Showcase-New-Data-at-the-27th-European-Academy-of-Dermatology-and-Venereology-EADV-Congress-Furthering-Innovation-for-Patients-with-Complex-Dermatological-Conditions\n",
      "http://lilly.mediaroom.com/2018-09-10-Lilly-Announces-Initiation-of-IXORA-R-Head-to-Head-Trial-Comparing-Taltz-R-and-Tremfya-R-in-Patients-with-Moderate-to-Severe-Plaque-Psoriasis\n",
      "http://lilly.mediaroom.com/2018-09-06-Lilly-Announces-Webcast-to-Discuss-EASD-Presentations\n",
      "http://lilly.mediaroom.com/2018-09-05-Lilly-Announces-Positive-Phase-3-Results-in-Study-of-Flortaucipir-PET-Imaging-Agent\n",
      "http://lilly.mediaroom.com/2018-08-30-Anne-White-Promoted-to-President-of-Lilly-Oncology\n",
      "http://lilly.mediaroom.com/2018-08-27-Lilly-to-Participate-in-Morgan-Stanley-Global-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2018-08-14-Elanco-Animal-Health-Announces-Pricing-of-2-0-Billion-of-Senior-Notes\n",
      "http://lilly.mediaroom.com/2018-08-02-Elanco-Animal-Health-Files-IPO-Registration-Statement\n",
      "http://lilly.mediaroom.com/2018-08-01-Lilly-Diabetes-Solution-Center-Now-Open-to-Help-People-with-Insulin-Affordability\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "http://lilly.mediaroom.com/2018-07-30-Lilly-Announces-Extension-of-Cancer-Research-Collaboration-with-Dana-Farber-Cancer-Institute\n",
      "http://lilly.mediaroom.com/2018-07-24-Lilly-Delivers-Strong-Second-Quarter-2018-Results-Revises-EPS-Guidance\n",
      "http://lilly.mediaroom.com/2018-07-24-Lilly-to-Separate-Elanco-Animal-Health-with-Initial-Public-Offering\n",
      "http://lilly.mediaroom.com/2018-07-20-Highlights-from-Lillys-Alzheimers-Disease-Pipeline-at-the-Alzheimers-Association-International-Conference-R-2018-AAIC-R-2018\n",
      "http://lilly.mediaroom.com/2018-07-19-Study-Published-in-The-Lancet-Shows-Benefit-of-Baricitinib-4-mg-for-the-Treatment-of-Systemic-Lupus-Erythematosus-SLE\n",
      "http://lilly.mediaroom.com/2018-07-19-Boehringer-Ingelheim-and-Lilly-announce-Tradjentas-CARMELINA-R-cardiovascular-outcome-trial-meets-primary-endpoint\n",
      "http://lilly.mediaroom.com/2018-07-19-Lillys-Once-Weekly-Trulicity-R-dulaglutide-Label-Updated-to-Include-Data-Showing-Benefits-for-Adults-with-Type-2-Diabetes-and-Chronic-Kidney-Disease\n",
      "http://lilly.mediaroom.com/2018-07-18-Pfizer-and-Lilly-Announce-Positive-Top-Line-Results-from-Phase-3-Trial-of-Tanezumab-for-the-Treatment-of-Osteoarthritis-OA-Pain\n",
      "http://lilly.mediaroom.com/2018-07-12-New-Lilly-Diabetes-helpline-to-Assist-People-Seeking-Solutions-to-Insulin-Affordability\n",
      "http://lilly.mediaroom.com/2018-06-29-Lilly-Announces-Initiation-of-the-Observational-Survey-of-the-Epidemiology-Treatment-and-Care-of-Migraine-OVERCOME-to-Advance-Understanding-of-Burden-Impact-and-Epidemiology-of-Migraine\n",
      "http://lilly.mediaroom.com/2018-06-28-Lilly-Confirms-Date-and-Conference-Call-for-Second-Quarter-2018-Financial-Results-Announcement\n",
      "http://lilly.mediaroom.com/2018-06-28-Lilly-Announces-Positive-Top-Line-Results-for-Second-Phase-3-Study-of-Taltz-R-ixekizumab-in-Ankylosing-Spondylitis-Radiographic-Axial-Spondyloarthritis-for-TNF-Inhibitor-Experienced-Patients\n",
      "http://lilly.mediaroom.com/2018-06-27-AHS-2018-Lillys-Emgality-TM-galcanezumab-gnlm-Significantly-Reduced-Monthly-Migraine-Headache-Days-in-Patients-with-Migraine-Who-Previously-Failed-BOTOX-R-onabotulinumtoxinA\n",
      "http://lilly.mediaroom.com/2018-06-27-AHS-2018-Lilly-Highlights-Positive-Phase-3-Results-from-the-Largest-Controlled-Preventive-Trial-in-Episodic-Cluster-Headache\n",
      "http://lilly.mediaroom.com/2018-06-25-Boehringer-Ingelheim-and-Lilly-announce-positive-top-line-Phase-III-data-results-for-empagliflozin-as-adjunct-to-insulin-in-type-1-diabetes\n",
      "http://lilly.mediaroom.com/2018-06-25-First-ever-Study-of-Lillys-Humulin-R-R-U-500-Administered-in-an-Insulin-Pump-Shows-Improved-A1C-in-People-with-Type-2-Diabetes\n",
      "http://lilly.mediaroom.com/2018-06-25-Lilly-to-Present-Phase-3-Data-at-AHS-2018-Highlighting-Innovative-Potential-Treatments-for-Migraine-and-Cluster-Headache\n",
      "http://lilly.mediaroom.com/2018-06-24-Real-World-Data-Show-Advantages-in-People-Treated-with-Lillys-Once-Weekly-Trulicity-R-dulaglutide-Compared-to-Those-Treated-with-Liraglutide-and-Exenatide-QW\n",
      "http://lilly.mediaroom.com/2018-06-23-New-Data-Presented-at-the-American-Diabetes-Association-78th-Scientific-Sessions-R-Reinforce-Potential-of-Lillys-Ultra-Rapid-Lispro-in-People-with-Type-1-and-Type-2-Diabetes\n",
      "http://lilly.mediaroom.com/2018-06-23-Jardiance-R-reduced-risk-of-kidney-disease-progression-in-adults-with-type-2-diabetes-and-established-cardiovascular-CV-disease-independent-of-control-of-conventional-CV-risk-factors\n",
      "http://lilly.mediaroom.com/2018-06-23-Investigational-Doses-of-Lillys-Once-Weekly-Trulicity-R-dulaglutide-Show-Promise-in-Delivering-Powerful-Efficacy-in-People-with-Type-2-Diabetes\n",
      "http://lilly.mediaroom.com/2018-06-22-U-S-District-Court-Rules-in-Favor-of-Lilly-in-Alimta-Vitamin-Regimen-Patent-Lawsuit\n",
      "http://lilly.mediaroom.com/2018-06-22-Lilly-Completes-Acquisition-of-ARMO-BioSciences\n",
      "http://lilly.mediaroom.com/2018-06-18-Lilly-Declares-Third-Quarter-2018-Dividend\n",
      "http://lilly.mediaroom.com/2018-06-12-Update-on-Phase-3-Clinical-Trials-of-Lanabecestat-for-Alzheimers-Disease\n",
      "http://lilly.mediaroom.com/2018-06-11-Lilly-to-Unveil-New-Data-at-the-Annual-European-Congress-of-Rheumatology-Furthering-Commitment-to-Scientific-Discovery-in-Immunology\n",
      "http://lilly.mediaroom.com/2018-06-05-Lilly-Recommends-Shareholders-Reject-Below-Market-Mini-Tender-Offer-by-TRC-Capital-Corp\n",
      "http://lilly.mediaroom.com/2018-06-05-DDW-2018-Patients-with-Moderate-to-Severe-Ulcerative-Colitis-Achieved-Clinical-and-Endoscopic-Remission-with-Mirikizumab-in-Phase-2-Trial\n",
      "http://lilly.mediaroom.com/2018-06-05-FDA-Expands-Lillys-ALIMTA-R-pemetrexed-Label-to-Include-Combination-with-KEYTRUDA-R-pembrolizumab-and-Carboplatin-as-First-Line-Treatment-for-Metastatic-Nonsquamous-Non-Small-Cell-Lung-Cancer-Irrespective-of-PD-L1-Expression\n",
      "http://lilly.mediaroom.com/2018-06-01-FDA-Approves-OLUMIANT-R-baricitinib-2-mg-Tablets-for-the-Treatment-of-Adults-with-Moderately-to-Severely-Active-Rheumatoid-Arthritis\n",
      "http://lilly.mediaroom.com/2018-06-01-Lilly-to-Showcase-New-Data-at-Digestive-Disease-Week-2018-for-Mirikizumab-in-Moderate-to-Severe-Ulcerative-Colitis\n",
      "http://lilly.mediaroom.com/2018-05-31-Lilly-to-Participate-in-Goldman-Sachs-Global-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2018-05-30-Lilly-to-Participate-in-Jefferies-Global-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2018-05-23-Sue-Mahony-to-Retire-as-President-of-Lilly-Oncology\n",
      "http://lilly.mediaroom.com/2018-05-22-Lillys-Taltz-R-ixekizumab-Receives-the-First-U-S-FDA-Approval-for-Label-Update-to-Include-Data-for-Psoriasis-Involving-the-Genital-Area\n",
      "http://lilly.mediaroom.com/2018-05-16-Lilly-Data-at-ASCO-Illustrate-Patient-Driven-Advances-in-Cancer-Care\n",
      "http://lilly.mediaroom.com/2018-05-15-Lillys-Galcanezumab-Meets-Primary-Endpoint-in-Phase-3-Study-Evaluating-Galcanezumab-for-the-Prevention-of-Episodic-Cluster-Headache\n",
      "http://lilly.mediaroom.com/2018-05-14-Lilly-to-Acquire-AurKa-Pharma\n",
      "http://lilly.mediaroom.com/2018-05-11-Lilly-to-Participate-in-UBS-Global-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2018-05-10-Lilly-Announces-Agreement-To-Acquire-ARMO-BioSciences\n",
      "http://lilly.mediaroom.com/2018-05-07-Lilly-Declares-Second-Quarter-2018-Dividend\n",
      "http://lilly.mediaroom.com/2018-05-01-Lilly-and-Local-Partners-Launch-Diabetes-Prevention-and-Management-Pilot-in-Three-Underserved-Neighborhoods-in-Indianapolis\n",
      "http://lilly.mediaroom.com/2018-04-30-Leena-Gandhi-M-D-Ph-D-to-Lead-Lilly-Oncology-Immuno-Oncology-Medical-Development\n",
      "http://lilly.mediaroom.com/2018-04-27-Lilly-to-Participate-in-Bank-of-America-Merrill-Lynch-Health-Care-Conference\n",
      "http://lilly.mediaroom.com/2018-04-25-Lilly-and-Chinas-NCCD-announce-collaboration-to-advance-scientific-understanding-and-care-for-people-living-with-diabetes-and-cardiovascular-disease\n",
      "http://lilly.mediaroom.com/2018-04-24-Lilly-Reports-Strong-First-Quarter-2018-Results-Raises-EPS-Guidance\n",
      "http://lilly.mediaroom.com/2018-04-24-AAN-2018-Lillys-Galcanezumab-Significantly-Reduced-Monthly-Migraine-Headache-Days-in-Patients-with-Migraine-Who-Previously-Failed-to-Respond-to-Multiple-Preventive-Therapies\n",
      "http://lilly.mediaroom.com/2018-04-23-FDA-Advisory-Committee-Recommends-the-Approval-of-Baricitinib-2mg-but-not-4mg-for-the-Treatment-of-Moderately-to-Severely-Active-Rheumatoid-Arthritis\n",
      "http://lilly.mediaroom.com/2018-04-20-Lilly-Reports-Additional-Top-Line-Results-from-CYRAMZA-R-ramucirumab-Phase-3-RANGE-Study-in-Advanced-or-Metastatic-Urothelial-Cancer\n",
      "http://lilly.mediaroom.com/2018-04-20-Lilly-to-Present-Phase-3-Data-at-AAN-2018-Reinforcing-Commitment-to-New-Innovative-Therapies-in-Migraine\n",
      "http://lilly.mediaroom.com/2018-04-16-Boehringer-Ingelheim-and-Lilly-announce-an-academic-collaboration-with-University-of-Oxford-to-investigate-the-effects-of-Jardiance-R-in-adults-with-chronic-kidney-disease\n",
      "http://lilly.mediaroom.com/2018-04-04-Lilly-Confirms-Date-and-Conference-Call-for-First-Quarter-2018-Financial-Results-Announcement\n",
      "http://lilly.mediaroom.com/2018-04-04-Lilly-and-Sigilon-Therapeutics-Announce-Strategic-Collaboration-to-Develop-Encapsulated-Cell-Therapies-for-the-Treatment-of-Type-1-Diabetes\n",
      "http://lilly.mediaroom.com/2018-04-04-Lilly-Announces-CYRAMZA-R-ramucirumab-Phase-3-REACH-2-Study-in-Second-Line-Hepatocellular-Carcinoma-Patients-Met-Overall-Survival-Endpoint\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "http://lilly.mediaroom.com/2018-03-09-Maura-Dickler-M-D-to-become-Vice-President-of-Late-Phase-Development-at-Lilly-Oncology\n",
      "http://lilly.mediaroom.com/2018-03-08-EFSD-JDRF-and-Lilly-Extend-Collaboration-Supporting-Type-1-Diabetes-Research\n",
      "http://lilly.mediaroom.com/2018-03-06-Boehringer-Ingelheim-and-Lilly-expand-heart-failure-program-for-Jardiance-R-with-new-exercise-capacity-trials\n",
      "http://lilly.mediaroom.com/2018-02-26-Lilly-Receives-Additional-FDA-Approval-for-Verzenio-abemaciclib-as-Initial-Treatment-for-Advanced-Breast-Cancer\n",
      "http://lilly.mediaroom.com/2018-02-26-New-Data-Show-Lillys-Trulicity-R-dulaglutide-in-Combination-with-an-SGLT-2-Inhibitor-Improves-Blood-Sugar-Control-in-People-with-Type-2-Diabetes\n",
      "http://lilly.mediaroom.com/2018-02-21-Lilly-to-Participate-in-Barclays-Global-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2018-02-20-Lilly-to-Participate-in-Cowen-Health-Care-Conference\n",
      "http://lilly.mediaroom.com/2018-02-20-Survey-Reveals-Many-People-with-Migraine-Live-with-Pain-Nearly-Half-of-Every-Month\n",
      "http://lilly.mediaroom.com/2018-02-19-AAD-2018-Treatment-with-Lillys-Taltz-R-ixekizumab-Resulted-in-Improvement-in-Impact-of-Genital-Psoriasis-on-Sexual-Activity\n",
      "http://lilly.mediaroom.com/2018-02-14-Lilly-to-Showcase-New-Data-for-Taltz-R-ixekizumab-and-Other-Products-Across-Immunology-Pipeline-at-AAD-Annual-Meeting\n",
      "http://lilly.mediaroom.com/2018-02-13-Lilly-Announces-Positive-Top-Line-Phase-3-Results-for-Taltz-R-ixekizumab-in-Ankylosing-Spondylitis-Radiographic-Axial-Spondyloarthritis\n",
      "http://lilly.mediaroom.com/2018-01-31-Lilly-Reports-Strong-Fourth-Quarter-and-Full-Year-2017-Revenue-Growth-Increases-2018-EPS-Guidance\n",
      "http://lilly.mediaroom.com/2018-01-26-Lilly-To-Present-At-Leerink-Partners-Global-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2018-01-08-Livongo-and-Lilly-Collaborate-on-Real-World-Diabetes-Research\n",
      "http://lilly.mediaroom.com/2018-01-05-Lilly-Confirms-Date-and-Conference-Call-for-Fourth-Quarter-2017-Financial-Results-Announcement\n",
      "http://lilly.mediaroom.com/2018-01-02-Lilly-to-Present-at-J-P-Morgan-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2017-12-18-Lilly-to-Participate-in-Goldman-Sachs-Healthcare-CEOs-Unscripted-Conference\n",
      "http://lilly.mediaroom.com/2017-12-14-Rimidi-and-Lilly-Collaborate-to-Personalize-Solutions-for-People-Using-Insulin\n",
      "http://lilly.mediaroom.com/2017-12-13-Lilly-Announces-2018-Financial-Guidance-and-Enhances-Outlook-Through-2020\n",
      "http://lilly.mediaroom.com/2017-12-11-Lilly-Announces-8-Percent-Dividend-Increase\n",
      "http://lilly.mediaroom.com/2017-12-11-FDA-Accepts-Biologics-License-Application-BLA-to-Review-Galcanezumab-for-the-Prevention-of-Migraine-in-Adults\n",
      "http://lilly.mediaroom.com/2017-12-11-Kimberly-Blackwell-M-D-to-become-Vice-President-of-Early-Phase-Development-and-Immuno-oncology-at-Lilly-Oncology\n",
      "http://lilly.mediaroom.com/2017-12-08-Lilly-Reports-Top-Line-Results-from-CYRAMZA-R-ramucirumab-Phase-3-Study-in-First-Line-Advanced-Gastric-Cancer\n",
      "http://lilly.mediaroom.com/2017-12-05-Lilly-Initiates-Clinical-Trial-to-Evaluate-the-Functionality-and-Safety-of-its-Automated-Insulin-Delivery-System\n",
      "http://lilly.mediaroom.com/2017-12-01-Lillys-Taltz-R-ixekizumab-Receives-U-S-FDA-Approval-for-the-Treatment-of-Active-Psoriatic-Arthritis\n",
      "http://lilly.mediaroom.com/2017-11-20-Lilly-Confirms-Date-and-Conference-Call-for-2018-Financial-Guidance-Announcement\n",
      "http://lilly.mediaroom.com/2017-11-17-Lilly-to-Participate-in-Evercore-ISI-2017-Biopharma-Catalyst-Deep-Dive-Conference\n",
      "http://lilly.mediaroom.com/2017-11-13-Jardiance-R-reduced-risk-of-cardiovascular-death-in-adults-with-type-2-diabetes-and-peripheral-artery-disease\n",
      "http://lilly.mediaroom.com/2017-11-13-Lilly-Appoints-Philip-Johnson-to-Senior-Vice-President-and-Treasurer\n",
      "http://lilly.mediaroom.com/2017-11-09-New-Data-on-FORTEO-R-teriparatide-rDNA-origin-injection-Showed-Reduced-Risk-for-New-Vertebral-and-Clinical-Fractures-in-Postmenopausal-Women-with-Severe-Osteoporosis\n",
      "http://lilly.mediaroom.com/2017-11-08-ACR-ARHP-2017-Long-Term-Use-of-Lillys-Taltz-R-ixekizumab-Shows-Efficacy-Improvements-in-Psoriatic-Arthritis-for-Patients-with-Prior-Inadequate-Response-or-Intolerance-to-TNF-Inhibitors\n",
      "http://lilly.mediaroom.com/2017-11-05-ACR-ARHP-2017-New-Analysis-Shows-Rheumatoid-Arthritis-Patients-Treated-with-Baricitinib-Reported-Greater-Improvements-in-Pain-Compared-to-Adalimumab-or-Placebo\n",
      "http://lilly.mediaroom.com/2017-10-30-Lilly-to-Present-New-Data-on-Immunology-Portfolio-at-ACR-ARHP-Annual-Meeting\n",
      "http://lilly.mediaroom.com/2017-10-25-Lilly-To-Participate-In-Credit-Suisse-26th-Annual-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2017-10-24-Lilly-Reports-Third-Quarter-Results-Announces-Strategic-Review-of-Elanco-Animal-Health\n",
      "http://lilly.mediaroom.com/2017-10-23-Lilly-announces-72-million-investment-in-diabetes-manufacturing-in-Indianapolis\n",
      "http://lilly.mediaroom.com/2017-10-18-Lilly-and-CureVac-Announce-Global-Collaboration-to-Develop-mRNA-Cancer-Vaccines\n",
      "http://lilly.mediaroom.com/2017-10-16-Lilly-Declares-Fourth-Quarter-2017-Dividend\n",
      "http://lilly.mediaroom.com/2017-10-16-Rapidly-Progressing-Advanced-Non-Small-Cell-Lung-Cancer-Patients-Shown-to-Benefit-in-New-CYRAMZA-R-ramucirumab-Phase-3-Subgroup-Analysis\n",
      "http://lilly.mediaroom.com/2017-10-12-FDA-Grants-Priority-Review-for-Potential-New-Indication-for-Lillys-Verzenio-TM-abemaciclib-as-Initial-Treatment-of-Advanced-Breast-Cancer\n",
      "http://lilly.mediaroom.com/2017-10-10-Lilly-Reports-Topline-Results-from-Phase-3-JUNIPER-Trial-Evaluating-Verzenio-TM-abemaciclib-in-KRAS-Mutated-Advanced-Non-Small-Cell-Lung-Cancer\n",
      "http://lilly.mediaroom.com/2017-10-06-Lilly-MONARCH-3-Study-Published-in-Journal-of-Clinical-Oncology-Demonstrates-Benefit-of-Verzenio-TM-abemaciclib-Plus-NSAI-in-Advanced-Breast-Cancer\n",
      "http://lilly.mediaroom.com/2017-10-05-U-S-Patent-and-Trademark-Office-Rules-In-Lillys-Favor-On-Alimta-Vitamin-Regimen-Patent\n",
      "http://lilly.mediaroom.com/2017-10-05-Additional-Delivery-of-Insulin-Ready-for-Distribution-in-Puerto-Rico\n",
      "http://lilly.mediaroom.com/2017-10-04-Lilly-Receives-U-S-FDA-Approval-of-Verzenio-TM-abemaciclib\n",
      "http://lilly.mediaroom.com/2017-10-04-Humalog-R-Junior-KwikPen-R-Now-Available-in-the-U-S-for-People-with-Diabetes\n",
      "http://lilly.mediaroom.com/2017-10-02-Lilly-Confirms-Date-and-Conference-Call-for-Third-Quarter-2017-Financial-Results-Announcement\n",
      "http://lilly.mediaroom.com/2017-09-29-Lilly-Announces-Senior-Leadership-Appointments-for-Finance-Research-Development-and-Manufacturing\n",
      "http://lilly.mediaroom.com/2017-09-25-Geisinger-and-Boehringer-Ingelheim-collaborate-to-create-a-predictive-model-to-help-improve-health-outcomes-for-people-with-type-2-diabetes-at-greatest-risk-of-serious-long-term-complications-including-cardiovascular-death\n",
      "http://lilly.mediaroom.com/2017-09-14-Baricitinib-Meets-Primary-Endpoint-in-Phase-2-Study-of-Patients-with-Moderate-to-Severe-Atopic-Dermatitis\n",
      "http://lilly.mediaroom.com/2017-09-12-Jardiance-R-empagliflozin-tablets-reduced-risk-of-cardiovascular-death-in-people-with-type-2-diabetes-and-established-cardiovascular-disease-independent-of-background-blood-sugar-control\n",
      "http://lilly.mediaroom.com/2017-09-11-Lilly-to-Present-New-Data-for-Olumiant-R-baricitinib-and-Taltz-R-ixekizumab-at-the-European-Academy-of-Dermatology-and-Venereology-EADV-Annual-Congress\n",
      "http://lilly.mediaroom.com/2017-09-10-Lilly-Builds-Upon-Body-of-Clinical-Evidence-for-CYRAMZA-R-ramucirumab-with-Phase-3-RANGE-Data-Demonstrating-Superior-Progression-Free-Survival-in-Advanced-or-Metastatic-Urothelial-Cancer\n",
      "http://lilly.mediaroom.com/2017-09-09-IHC-2017-Lillys-Lasmiditan-Significantly-Reduces-Pain-in-Patients-with-Migraine\n",
      "http://lilly.mediaroom.com/2017-09-08-IHC-2017-Lillys-Galcanezumab-Demonstrates-Positive-Long-Term-Safety-Results-for-up-to-12-Months-in-Patients-with-Migraine\n",
      "http://lilly.mediaroom.com/2017-09-07-Lilly-Takes-Steps-to-Streamline-Business-Invest-in-New-Medicines-and-Drive-Growth\n",
      "http://lilly.mediaroom.com/2017-09-06-Lilly-to-Present-New-Data-for-Galcanezumab-and-Lasmiditan-at-the-18th-Congress-of-the-International-Headache-Society-IHC\n",
      "http://lilly.mediaroom.com/2017-08-30-Lilly-to-File-Baricitinib-Resubmission-to-U-S-FDA-before-end-of-January-2018\n",
      "http://lilly.mediaroom.com/2017-08-29-New-Phase-3-Data-for-Abemaciclib-and-Ramucirumab-Presented-at-ESMO-2017-Congress\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "http://lilly.mediaroom.com/2017-08-28-Lilly-to-Participate-in-Morgan-Stanley-Global-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2017-08-04-Lilly-Announces-Positive-Results-for-Second-Phase-3-Study-of-Lasmiditan-for-the-Acute-Treatment-of-Migraine\n",
      "http://lilly.mediaroom.com/2017-07-31-Boehringer-Ingelheim-and-Lilly-to-support-new-American-College-of-Cardiology-program-to-highlight-the-increasingly-important-role-of-cardiologists-in-reducing-cardiovascular-risk-and-cardiovascular-death-in-people-with-type-2-diabetes\n",
      "http://lilly.mediaroom.com/2017-07-25-Lilly-Reports-Second-Quarter-Results\n",
      "http://lilly.mediaroom.com/2017-07-25-Lilly-and-Incyte-Provide-Update-on-Baricitinib\n",
      "http://lilly.mediaroom.com/2017-07-24-Lilly-and-Nektar-Therapeutics-Announce-Alliance-to-Develop-and-Commercialize-NKTR-358-A-Novel-Autoimmune-Therapy\n",
      "http://lilly.mediaroom.com/2017-07-12-Lilly-Reaches-Settlement-Agreement-in-U-S-Cialis-Patent-Litigation\n",
      "http://lilly.mediaroom.com/2017-07-12-Eli-Lilly-and-Company-to-Present-More-Than-40-Abstracts-at-the-Alzheimers-Association-International-Conference-R-2017-AAIC-R-2017\n",
      "http://lilly.mediaroom.com/2017-07-10-Renowned-Television-Personality-Don-Francisco-Introduces-New-Initiative-to-Help-Dispel-Myths-About-Diabetes-and-Insulin-Treatment\n",
      "http://lilly.mediaroom.com/2017-07-10-FDA-Grants-Priority-Review-for-Lillys-Abemaciclib-for-the-Treatment-of-Advanced-Breast-Cancer\n",
      "http://lilly.mediaroom.com/2017-07-07-UK-Supreme-Court-Rules-In-Lillys-Favor-On-Alimta-Vitamin-Regimen-Patents\n",
      "http://lilly.mediaroom.com/2017-07-06-Lilly-Confirms-Date-and-Conference-Call-for-Second-Quarter-2017-Financial-Results-Announcement\n",
      "http://lilly.mediaroom.com/2017-07-06-Lilly-and-Purdue-University-Announce-Strategic-Research-Collaboration\n",
      "http://lilly.mediaroom.com/2017-07-03-Japan-Ministry-of-Health-Labor-and-Welfare-MHLW-Grants-Marketing-Approval-For-Olumiant-R-baricitinib-for-the-Treatment-of-Rheumatoid-Arthritis\n",
      "http://lilly.mediaroom.com/2017-06-27-Lilly-Diabetes-Brings-an-Extra-Splash-of-Summertime-Fun-and-Inspiration-to-Diabetes-Camps-with-Launch-of-Annual-Camp-Care-Package-Speaker-Tour\n",
      "http://lilly.mediaroom.com/2017-06-21-Eli-Lilly-and-Company-Unveils-Expanded-Biotechnology-Center-in-San-Diego\n",
      "http://lilly.mediaroom.com/2017-06-19-Lilly-Declares-Third-Quarter-2017-Dividend\n",
      "http://lilly.mediaroom.com/2017-06-16-EULAR-2017-Lillys-Taltz-R-ixekizumab-Demonstrated-No-Progression-or-Minimal-Progression-of-Radiographic-Disease-in-Patients-with-Psoriatic-Arthritis-Through-52-Weeks\n",
      "http://lilly.mediaroom.com/2017-06-16-New-Safety-and-Long-Term-Efficacy-Data-from-Baricitinib-Clinical-Trials-in-Patients-with-Moderate-to-Severe-Rheumatoid-Arthritis-Presented-at-EULAR-2017\n",
      "http://lilly.mediaroom.com/2017-06-15-EULAR-2017-Lillys-Taltz-R-ixekizumab-Demonstrated-Significant-Improvements-in-Disease-Signs-and-Symptoms-at-24-Weeks-Among-Patients-with-Active-Psoriatic-Arthritis-Who-Had-Prior-Inadequate-Response-or-Intolerance-to-TNF-Inhibitors\n",
      "http://lilly.mediaroom.com/2017-06-13-Lilly-to-Present-New-Data-on-Olumiant-R-baricitinib-in-Rheumatoid-Arthritis-and-Taltz-R-ixekizumab-in-Psoriatic-Arthritis-at-the-Annual-European-Congress-of-Rheumatology-EULAR-2017\n",
      "http://lilly.mediaroom.com/2017-06-13-U-S-FDA-Approves-Humalog-R-Junior-KwikPen-R-for-the-Treatment-of-Diabetes\n",
      "http://lilly.mediaroom.com/2017-06-13-Jardiance-R-empagliflozin-analysis-reinforces-established-safety-profile\n",
      "http://lilly.mediaroom.com/2017-06-13-Pfizer-and-Lilly-Receive-FDA-Fast-Track-Designation-for-Tanezumab\n",
      "http://lilly.mediaroom.com/2017-06-12-Jardiance-R-empagliflozin-tablets-to-be-studied-in-chronic-kidney-disease\n",
      "http://lilly.mediaroom.com/2017-06-10-Lillys-Galcanezumab-Significantly-Reduces-Number-of-Migraine-Headache-Days-for-Patients-with-Migraine-New-Results-Presented-at-AHS\n",
      "http://lilly.mediaroom.com/2017-06-09-IDF-in-partnership-with-Lilly-announces-second-phase-of-BRIDGES-programme-funding-for-translational-research-in-diabetes-with-focus-on-secondary-prevention\n",
      "http://lilly.mediaroom.com/2017-06-08-Lilly-to-Present-Late-Breaking-Data-for-Galcanezumab-and-Lasmiditan-at-the-American-Headache-Society-Annual-Scientific-Meeting\n",
      "http://lilly.mediaroom.com/2017-06-08-Lilly-Announces-Webcast-to-Discuss-Pain-Management-Portfolio\n",
      "http://lilly.mediaroom.com/2017-06-08-Lilly-Announces-Strategic-Collaboration-with-KeyBioscience-AG\n",
      "http://lilly.mediaroom.com/2017-06-03-Lilly-Builds-Upon-Body-of-Data-for-Abemaciclib-with-Phase-3-MONARCH-2-Data-Demonstrating-Superior-Progression-Free-Survival-in-Advanced-Breast-Cancer\n",
      "http://lilly.mediaroom.com/2017-06-01-Boehringer-Ingelheim-and-Lilly-Diabetes-Alliance-to-Present-33-Abstracts-at-the-American-Diabetes-Associations-77th-Scientific-Sessions-R\n",
      "http://lilly.mediaroom.com/2017-06-01-Derica-Rice-to-Retire-as-Lilly-Chief-Financial-Officer\n",
      "http://lilly.mediaroom.com/2017-05-31-Lilly-to-Participate-in-Goldman-Sachs-Global-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2017-05-31-Lilly-Announces-Phase-3-RANGE-Urothelial-Cancer-Trial-of-CYRAMZA-R-ramucirumab-Met-Primary-Endpoint-Improving-Progression-Free-Survival\n",
      "http://lilly.mediaroom.com/2017-05-17-Lilly-to-Present-Results-from-Pivotal-Breast-Cancer-Study-of-Abemaciclib-and-New-Portfolio-Data-at-ASCO-2017\n",
      "http://lilly.mediaroom.com/2017-05-16-Actress-Angela-Bassett-joins-For-Your-SweetHeart-TM-to-urge-people-with-diabetes-to-know-their-heart-disease-risk-in-honor-of-her-mom\n",
      "http://lilly.mediaroom.com/2017-05-12-Lilly-Announces-Positive-Results-for-Three-Phase-3-Studies-of-Galcanezumab-for-the-Prevention-of-Episodic-and-Chronic-Migraine\n",
      "http://lilly.mediaroom.com/2017-05-10-Lilly-to-Participate-in-Bernstein-Strategic-Decisions-Conference\n",
      "http://lilly.mediaroom.com/2017-05-10-Leigh-Ann-Pusey-Joins-Lilly-as-Senior-Vice-President-of-Corporate-Affairs-and-Communications\n",
      "http://lilly.mediaroom.com/2017-05-03-Lilly-to-Participate-in-UBS-Global-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2017-05-02-Lilly-Announces-Webcast-to-Discuss-Oncology-Pipeline\n",
      "http://lilly.mediaroom.com/2017-05-01-Lilly-Declares-Second-Quarter-2017-Dividend\n",
      "http://lilly.mediaroom.com/2017-04-25-Lilly-Reports-First-Quarter-2017-Results\n",
      "http://lilly.mediaroom.com/2017-04-24-Lilly-Announces-Phase-3-MONARCH-3-Breast-Cancer-Study-of-Abemaciclib-Demonstrated-Superior-Progression-Free-Survival-at-Interim-Analysis\n",
      "http://lilly.mediaroom.com/2017-04-20-Lilly-to-Present-Data-for-Galcanezumab-for-the-Prevention-of-Migraine-at-the-American-Academy-of-Neurology-AAN-Annual-Meeting\n",
      "http://lilly.mediaroom.com/2017-04-14-U-S-FDA-Issues-Complete-Response-Letter-for-Baricitinib\n",
      "http://lilly.mediaroom.com/2017-04-11-Lilly-Confirms-Date-and-Conference-Call-for-First-Quarter-2017-Financial-Results-Announcement\n",
      "http://lilly.mediaroom.com/2017-04-07-Life-with-Type-1-Diabetes-Made-a-Little-Easier-through-Lilly-Diabetes-Scholarship-Donations-for-Camps-College-and-Conferences\n",
      "http://lilly.mediaroom.com/2017-04-04-Lilly-and-Ohio-University-Heritage-College-of-Osteopathic-Medicine-Partner-on-Rotation-Program-for-Medical-Students\n",
      "http://lilly.mediaroom.com/2017-03-23-Lilly-and-the-William-Sansum-Diabetes-Center-announce-a-five-year-research-collaboration\n",
      "http://lilly.mediaroom.com/2017-03-20-Lilly-Announces-Phase-3-MONARCH-2-Breast-Cancer-Study-of-Abemaciclib-Met-Primary-Endpoint-of-Progression-Free-Survival\n",
      "http://lilly.mediaroom.com/2017-03-17-First-dedicated-outcome-trials-of-empagliflozin-in-chronic-heart-failure-initiated\n",
      "http://lilly.mediaroom.com/2017-03-04-New-Head-to-Head-Data-Shows-Significantly-Higher-Response-Rates-for-Lillys-Taltz-R-ixekizumab-Compared-to-Stelara-R-ustekinumab-in-Patients-with-Moderate-to-Severe-Plaque-Psoriasis\n",
      "http://lilly.mediaroom.com/2017-03-03-Lilly-Diabetes-Becomes-Official-Diabetes-Health-Partner-of-NASCAR-R\n",
      "http://lilly.mediaroom.com/2017-03-02-Lilly-Announces-Changes-in-Senior-Management\n",
      "http://lilly.mediaroom.com/2017-03-01-Lilly-Completes-Acquisition-of-CoLucid-Pharmaceuticals\n",
      "http://lilly.mediaroom.com/2017-02-28-Lilly-to-Present-New-Data-for-Taltz-R-ixekizumab-in-Psoriasis-and-Psoriatic-Arthritis-at-the-American-Academy-of-Dermatology-AAD-Annual-Meeting\n",
      "http://lilly.mediaroom.com/2017-02-15-Additional-results-from-pivotal-RA-BEAM-study-published-in-New-England-Journal-of-Medicine-show-baricitinib-treated-patients-demonstrated-sustained-improvement-in-rheumatoid-arthritis-compared-to-adalimumab-and-placebo\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "http://lilly.mediaroom.com/2017-02-13-European-Commission-Approves-Once-Daily-Olumiant-Tablets-for-Treatment-of-Adults-with-Moderate-to-Severe-Active-Rheumatoid-Arthritis\n",
      "http://lilly.mediaroom.com/2017-02-09-Lilly-To-Present-At-Leerink-Partners-Global-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2017-02-09-Carolyn-R-Bertozzi-Ph-D-Elected-to-Lilly-Board-of-Directors\n",
      "http://lilly.mediaroom.com/2017-02-08-Lilly-to-Present-at-Cowen-Health-Care-Conference\n",
      "http://lilly.mediaroom.com/2017-02-08-Lillys-Trulicity-R-dulaglutide-Label-Updated-to-Include-Use-in-Combination-with-Basal-Insulin-for-Adults-with-Type-2-Diabetes\n",
      "http://lilly.mediaroom.com/2017-02-02-Japan-IP-High-Court-Rules-In-Lillys-Favor-On-Alimta-Vitamin-Regimen-Patents\n",
      "http://lilly.mediaroom.com/2017-01-31-Lilly-Reports-Fourth-Quarter-and-Full-Year-2016-Results\n",
      "http://lilly.mediaroom.com/2017-01-30-Lilly-Revises-Time-for-Conference-Call-for-Fourth-Quarter-2016-Financial-Results-Announcement\n",
      "http://lilly.mediaroom.com/2017-01-18-Lilly-and-CoLucid-Pharmaceuticals-Announce-Agreement-for-Lilly-To-Acquire-CoLucid\n",
      "http://lilly.mediaroom.com/2017-01-13-U-S-FDA-Extends-Review-Period-for-Baricitinib-an-Investigational-Rheumatoid-Arthritis-Treatment\n",
      "http://lilly.mediaroom.com/2017-01-12-U-S-Court-of-Appeals-Rules-In-Lillys-Favor-On-Alimta-Vitamin-Regimen-Patent\n",
      "http://lilly.mediaroom.com/2017-01-11-Lilly-and-Merck-Expand-Immuno-Oncology-Collaboration\n",
      "http://lilly.mediaroom.com/2017-01-05-Lilly-Confirms-Date-and-Conference-Call-for-Fourth-Quarter-2016-Financial-Results-Announcement\n",
      "http://lilly.mediaroom.com/2017-01-05-Lilly-to-Adjust-Organization-and-Leadership-Structure-to-Better-Align-with-Growth-Opportunities\n",
      "http://lilly.mediaroom.com/2017-01-04-U-S-FDA-approves-supplemental-New-Drug-Applications-to-include-landmark-data-in-product-labels-for-Synjardy-R-empagliflozin-metformin-hydrochloride-Synjardy-R-XR-empagliflozin-metformin-hydrochloride-extended-release-and-Glyxambi-R-empagliflozi\n",
      "http://lilly.mediaroom.com/2017-01-03-Lilly-to-Present-at-J-P-Morgan-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2016-12-16-Boehringer-Ingelheim-and-Lilly-Welcome-New-Recommendation-for-Jardiance-R-empagliflozin-Tablets-in-Updated-American-Diabetes-Associations-2017-Standards\n",
      "http://lilly.mediaroom.com/2016-12-16-CHMP-Recommends-Approval-of-Lillys-Baricitinib-for-the-Treatment-of-Adults-with-Moderate-to-Severe-Active-Rheumatoid-Arthritis-RA\n",
      "http://lilly.mediaroom.com/2016-12-15-BASAGLAR-R-insulin-glargine-injection-100-units-mL-A-Long-Acting-Basal-Insulin-Is-Now-Available-in-U-S\n",
      "http://lilly.mediaroom.com/2016-12-15-Lilly-Provides-2017-Financial-Guidance-and-2016-Update-Reaffirms-Financial-Expectations-Through-the-Remainder-of-the-Decade\n",
      "http://lilly.mediaroom.com/2016-12-13-Lilly-Announces-Program-to-Provide-Insulin-at-Discounted-Prices\n",
      "http://lilly.mediaroom.com/2016-12-12-Lilly-Announces-Dividend-Increase\n",
      "http://lilly.mediaroom.com/2016-12-12-U-S-FDA-approves-Synjardy-R-XR-empagliflozin-metformin-hydrochloride-extended-release-tablets-for-adults-with-type-2-diabetes\n",
      "http://lilly.mediaroom.com/2016-12-09-Lilly-and-AstraZeneca-to-Develop-Second-Potentially-Disease-Modifying-Treatment-for-Alzheimers-Disease\n",
      "http://lilly.mediaroom.com/2016-12-08-Lilly-Announces-Detailed-Results-of-Solanezumab-Phase-3-EXPEDITION3-Study-at-the-Clinical-Trials-on-Alzheimers-Disease-CTAD-2016-Meeting\n",
      "http://lilly.mediaroom.com/2016-12-08-Lilly-Presents-neoMONARCH-Phase-2-Data-on-Abemaciclib-in-Early-Stage-Breast-Cancer\n",
      "http://lilly.mediaroom.com/2016-12-05-U-S-FDA-approves-Jardiance-R-empagliflozin-tablets-to-reduce-the-risk-of-cardiovascular-death-in-adults-with-type-2-diabetes-and-established-cardiovascular-disease\n",
      "http://lilly.mediaroom.com/2016-12-02-Lilly-Confirms-Date-and-Conference-Call-for-2017-Financial-Guidance-Announcement\n",
      "http://lilly.mediaroom.com/2016-11-30-Lilly-Introduces-Scholars-Programs-for-Florida-A-M-Universitys-and-Howard-Universitys-Business-Students\n",
      "http://lilly.mediaroom.com/2016-11-23-Lilly-Announces-Top-Line-Results-of-Solanezumab-Phase-3-Clinical-Trial\n",
      "http://lilly.mediaroom.com/2016-11-22-Survey-Reveals-Most-People-Dont-Know-Heart-Disease-Is-the-No-1-Killer-of-People-with-Type-2-Diabetes\n",
      "http://lilly.mediaroom.com/2016-11-14-New-Analyses-of-Phase-3-Trials-Show-Improvements-in-Rheumatoid-Arthritis-Symptoms-Following-Treatment-with-Baricitinib-Across-Diverse-Population-of-Patients\n",
      "http://lilly.mediaroom.com/2016-11-14-Baricitinib-Demonstrates-Early-Response-Compared-to-Placebo-and-Significant-Improvement-Compared-to-Adalimumab-in-Patient-Reported-Outcomes\n",
      "http://lilly.mediaroom.com/2016-11-13-Jardiance-R-empagliflozin-consistently-reduced-the-risk-of-cardiovascular-death-in-adults-with-type-2-diabetes-regardless-of-the-type-of-cardiovascular-disease-at-baseline\n",
      "http://lilly.mediaroom.com/2016-11-03-Lilly-Presents-Clinical-Efficacy-Safety-and-Patient-Reported-Outcomes-Data-of-Baricitinib-in-Patients-with-Rheumatoid-Arthritis-at-2016-American-College-of-Rheumatology-Annual-Meeting\n",
      "http://lilly.mediaroom.com/2016-11-02-New-data-from-pivotal-RA-BEACON-study-show-significant-improvement-in-patient-reported-outcomes-in-rheumatoid-arthritis-patients-treated-with-baricitinib-compared-to-placebo\n",
      "http://lilly.mediaroom.com/2016-10-31-New-Edition-of-Online-Tool-to-Measure-Cancer-Progress-to-Launch-at-World-Cancer-Congress\n",
      "http://lilly.mediaroom.com/2016-10-25-Lilly-Reports-Third-Quarter-2016-Results\n",
      "http://lilly.mediaroom.com/2016-10-19-FDA-Approves-Lillys-LARTRUVO-TM-olaratumab-in-Combination-with-Doxorubicin-for-Soft-Tissue-Sarcoma\n",
      "http://lilly.mediaroom.com/2016-10-17-Lilly-Declares-Fourth-Quarter-2016-Dividend\n",
      "http://lilly.mediaroom.com/2016-10-17-Lilly-Partners-with-the-National-Cancer-Institute-to-Accelerate-Cancer-Research-through-New-Program-under-Cancer-Moonshot-Initiative\n",
      "http://lilly.mediaroom.com/2016-10-12-Eli-Lilly-and-Company-Sponsors-Arthritis-Foundation-Living-Your-Yes-With-RA-an-Initiative-to-Provide-Resources-for-the-Rheumatoid-Arthritis-Community\n",
      "http://lilly.mediaroom.com/2016-10-11-Lilly-to-Participate-in-Credit-Suisse-2016-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2016-10-11-Leading-Experts-Warn-Global-Goal-to-Cure-or-Treat-Alzheimers-Disease-By-2025-is-at-Risk-Offer-Solutions-to-Adjust-Course\n",
      "http://lilly.mediaroom.com/2016-10-09-New-Data-on-the-Combination-of-Lillys-ALIMTA-R-pemetrexed-and-Mercks-KEYTRUDA-R-pembrolizumab-Show-a-Near-Doubling-of-Objective-Response-Rate-Compared-to-Standard-of-Care-Alone-in-First-Line-Metastatic-Non-Small-Cell-Lung-Cancer\n",
      "http://lilly.mediaroom.com/2016-10-05-Lilly-Highlights-Advancements-in-its-Oncology-Portfolio-with-New-Data-at-ESMO-2016\n",
      "http://lilly.mediaroom.com/2016-10-05-Elanco-Animal-Health-Enters-Agreement-to-Acquire-Boehringer-Ingelheim-Vetmedicas-U-S-Feline-Canine-and-Rabies-Vaccines-Portfolio\n",
      "http://lilly.mediaroom.com/2016-10-04-Lilly-Confirms-Date-And-Conference-Call-For-Third-Quarter-2016-Financial-Results-Announcement\n",
      "http://lilly.mediaroom.com/2016-09-27-Lilly-to-Present-Latest-Data-for-Taltz-R-ixekizumab-in-Psoriasis-at-the-European-Academy-of-Dermatology-and-Venereology-EADV-Annual-Congress\n",
      "http://lilly.mediaroom.com/2016-09-16-CHMP-Recommends-Approval-of-Lillys-Olaratumab-in-Combination-with-Doxorubicin-for-Advanced-Soft-Tissue-Sarcoma\n",
      "http://lilly.mediaroom.com/2016-09-15-Boston-Mayor-Walsh-and-the-Alzheimers-Association-Massachusetts-New-Hampshire-Chapter-Receive-Alzheimers-Readiness-Award\n",
      "http://lilly.mediaroom.com/2016-09-14-Levi-Garraway-M-D-Ph-D-to-become-Senior-Vice-President-of-Global-Oncology-at-Lilly-Succeeding-Richard-Gaynor-M-D-Who-is-Retiring-after-a-Distinguished-Career\n",
      "http://lilly.mediaroom.com/2016-08-31-Jamere-Jackson-Elected-to-Lilly-Board-of-Directors\n",
      "http://lilly.mediaroom.com/2016-08-24-Lilly-to-Participate-in-Morgan-Stanley-Global-Healthcare-Conference\n",
      "http://lilly.mediaroom.com/2016-08-22-Lilly-and-AstraZeneca-Receive-FDA-Fast-Track-Designation-for-AZD3293-an-Investigational-Treatment-for-Early-Alzheimers-Disease\n",
      "http://lilly.mediaroom.com/2016-08-10-Lilly-announces-Joshua-Smiley-Anat-Ashkenazi-appointed-to-new-roles-Thomas-Grein-retires\n",
      "http://lilly.mediaroom.com/2016-08-10-Lilly-Provides-Update-on-MONARCH-2-Phase-3-Trial-of-Abemaciclib\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "http://lilly.mediaroom.com/2016-07-27-New-Studies-Suggest-Relationship-between-Tau-Pathology-and-Progression-of-Alzheimers-Disease\n",
      "http://lilly.mediaroom.com/2016-07-27-John-C-Lechleiter-to-Retire-as-Lilly-CEO-Board-Elects-David-A-Ricks-as-Successor\n",
      "http://lilly.mediaroom.com/2016-07-26-Lilly-Reports-Second-Quarter-2016-Results-Provides-Financial-Expectations-Through-the-Remainder-of-the-Decade\n",
      "http://lilly.mediaroom.com/2016-07-21-Diversity-of-Lillys-Alzheimers-Disease-Pipeline-Showcased-at-the-Alzheimers-Association-International-Conference-R-2016-AAIC-R-2016\n",
      "http://lilly.mediaroom.com/2016-07-19-U-S-FDA-expands-indication-for-type-2-diabetes-treatment-Synjardy-R-empagliflozin-metformin-hydrochloride-to-include-treatment-naive-adults\n",
      "http://lilly.mediaroom.com/2016-07-13-Lilly-and-Boehringer-Ingelheim-Announce-Clinical-Trial-Collaboration-in-Metastatic-Breast-Cancer\n",
      "http://lilly.mediaroom.com/2016-07-12-Lilly-and-Howard-University-partner-on-summer-Medical-Scientific-Fellowship\n",
      "http://lilly.mediaroom.com/2016-07-06-Lilly-Diabetes-Welcomes-Acclaimed-Singer-Songwriter-Crystal-Bowersox-as-Newest-Spokesperson\n",
      "http://lilly.mediaroom.com/2016-06-28-FDA-Advisory-Committee-recommends-approval-of-Jardiance-R-empagliflozin-for-cardiovascular-indication-in-12-11-vote\n",
      "http://lilly.mediaroom.com/2016-06-28-Lilly-Confirms-Date-And-Conference-Call-For-Second-Quarter-2016-Financial-Results-Announcement\n",
      "http://lilly.mediaroom.com/2016-06-27-Lilly-Convenes-Leaders-at-National-Mayors-Conference-to-Address-Impact-of-Alzheimers-Disease-on-Local-Communities\n",
      "http://lilly.mediaroom.com/2016-06-23-Diabetes-Scholars-Foundation-Announces-2016-Scholarship-Recipients\n",
      "http://lilly.mediaroom.com/2016-06-20-Lilly-Declares-Third-Quarter-2016-Dividend\n",
      "http://lilly.mediaroom.com/2016-06-14-German-Supreme-Court-Grants-Lilly-Appeal-in-Alimta-R-Vitamin-Regimen-Patent-Lawsuit\n",
      "http://lilly.mediaroom.com/2016-06-13-Aarti-Shah-named-chief-information-officer\n",
      "http://lilly.mediaroom.com/2016-06-12-New-Data-Show-Lillys-Once-Weekly-Trulicity-R-dulaglutide-in-Combination-with-Insulin-Glargine-Improves-Glycemic-Control-in-People-with-Type-2-Diabetes\n",
      "http://lilly.mediaroom.com/2016-06-12-New-Jardiance-R-empagliflozin-data-show-that-reduced-risk-for-cardiovascular-CV-death-was-consistent-across-age-groups-in-adults-with-type-2-diabetes\n",
      "http://lilly.mediaroom.com/2016-06-11-New-study-results-show-Tradjenta-R-linagliptin-reduces-blood-sugar-in-adults-with-type-2-diabetes-at-risk-for-kidney-impairment\n",
      "http://lilly.mediaroom.com/2016-06-11-New-Study-Findings-Underscore-Importance-of-Physician-Patient-Communication-on-Insulin-Adherence-and-Outcomes\n",
      "http://lilly.mediaroom.com/2016-06-09-Data-in-The-Lancet-Show-Olaratumab-Plus-Doxorubicin-Offered-11-8-Month-Increase-in-Overall-Survival-in-Patients-with-Advanced-Soft-Tissue-Sarcoma-as-Reported-by-Lilly-and-Memorial-Sloan-Kettering-Researchers\n",
      "http://lilly.mediaroom.com/2016-06-09-Lilly-and-American-Migraine-Foundation-Announce-1-Million-Grant-for-Launch-of-First-Patient-Registry-to-Advance-Research-and-Development-in-Migraine\n",
      "http://lilly.mediaroom.com/2016-06-09-Patient-reported-outcomes-across-phase-3-studies-of-baricitinib-demonstrate-statistically-significant-improvements-in-physical-function-and-quality-of-life-symptoms-in-patients-with-rheumatoid-arthritis-RA\n",
      "http://lilly.mediaroom.com/2016-06-09-Baricitinib-significantly-reduces-joint-damage-progression-in-rheumatoid-arthritis-in-patients-who-do-not-respond-to-conventional-DMARDs\n",
      "http://lilly.mediaroom.com/2016-06-08-Studies-Demonstrate-Lillys-Taltz-R-ixekizumab-Maintained-or-Achieved-High-Levels-of-Skin-Clearance-for-Patients-with-Moderate-to-Severe-Plaque-Psoriasis-through-60-Weeks-Results-Published-in-the-New-England-Journal-of-Medicine\n",
      "http://lilly.mediaroom.com/2016-06-07-Results-of-Clinical-and-Patient-Reported-Outcomes-Data-for-Baricitinib-in-Patients-with-Rheumatoid-Arthritis-to-be-Presented-at-Annual-European-Congress-of-Rheumatology-EULAR-2016\n",
      "http://lilly.mediaroom.com/2016-06-05-Early-Phase-Immuno-Oncology-Studies-of-Lillys-ALIMTA-R-pemetrexed-and-CYRAMZA-R-ramucirumab-with-Mercks-KEYTRUDA-R-pembrolizumab-Show-Encouraging-Results-in-Non-Small-Cell-Lung-Cancer\n",
      "http://lilly.mediaroom.com/2016-06-03-Lilly-Announces-Results-from-MONARCH-1-Trial-of-Abemaciclib-Monotherapy\n",
      "http://lilly.mediaroom.com/2016-06-01-Lilly-Announces-Diabetes-Commercial-Update-Investor-Call\n",
      "http://lilly.mediaroom.com/2016-05-31-Lilly-Announces-Webcast-to-Discuss-Abemaciclib-Data\n"
     ]
    }
   ],
   "source": [
    "data = []\n",
    "offset = 0\n",
    "\n",
    "ticker = 'lly'\n",
    "\n",
    "sector = get_sector(ticker)\n",
    "\n",
    "index_ticker = '^GSPC'\n",
    "# select by value \n",
    "\n",
    "stock_hist = get_df(ticker)\n",
    "index_hist = get_df(index_ticker)\n",
    "\n",
    "# create break\n",
    "while True:\n",
    "    \n",
    "    headers = {\"User-Agent\": \"Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/94.0.4606.81 Safari/537.36\"}\n",
    "    \n",
    "    s = requests.Session()\n",
    "    html = requests.get(f'https://lilly.mediaroom.com/index.php?s=9042&l=100&o={offset}/', headers=headers)\n",
    "    \n",
    "\n",
    "    content = BeautifulSoup(html.content) \n",
    "\n",
    "    articles = content.find_all('div',attrs={'class': 'wd_item_wrapper'})\n",
    "        \n",
    "    if not articles:\n",
    "        break\n",
    "\n",
    "   \n",
    "    for article in articles:\n",
    "        date = article.find('div', attrs={'wd_date'}).text.lstrip()\n",
    "        title = article.find('div', attrs={'wd_title'}).text\n",
    "        url = article.find('div', attrs={'wd_title'}).get('href')\n",
    "        \n",
    "        date = date.lstrip().rstrip()    # remove starting and trailing whitespaces\n",
    "        title = title.lstrip().rstrip() \n",
    "        \n",
    "        url = article.find('a').get('href')\n",
    "        date = datetime.strptime(date, '%B %d, %Y').date()\n",
    "        print(url)\n",
    "        content = get_content_header(url, 'meta', {'property':'og:description'})\n",
    "        if date < datetime(2014, 1, 1).date():\n",
    "            past_last_date = True\n",
    "            break        \n",
    "        \n",
    "        pct_change = changes_from_press(stock_hist, date, 1)\n",
    "        if pct_change != None:\n",
    "            index_price, norm_price = normalise_to_index(pct_change, date, index_hist)\n",
    "        else:\n",
    "            index_price, norm_price = (None, None)\n",
    "\n",
    "        data.append([str(date), title, url, content, pct_change, index_price, norm_price])\n",
    "    if past_last_date == True: break    \n",
    "    offset = offset + 100\n",
    "\n",
    "\n",
    "save_data(data, ticker, sector)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "e20f97e8",
   "metadata": {},
   "outputs": [],
   "source": [
    "from bs4 import BeautifulSoup as bs\n",
    "\n",
    "\n",
    "url = 'http://lilly.mediaroom.com/2023-06-02-Lilly-Highlights-Verzenio-R-abemaciclib-and-Jaypirca-TM-pirtobrutinib-Data-at-2023-ASCO-R-Annual-Meeting'\n",
    "import urllib.request\n",
    "user_agent = 'Mozilla/5.0 (Windows; U; Windows NT 5.1; en-US; rv:1.9.0.7) Gecko/2009021910 Firefox/3.0.7'\n",
    "\n",
    "headers={'User-Agent':user_agent,} \n",
    "\n",
    "request = urllib.request.Request(url, None, headers) #The assembled request\n",
    "\n",
    "\n",
    "response = urllib.request.urlopen(request, timeout=8)\n",
    "\n",
    "soup = bs(response, 'html.parser')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "18d0ab1d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<meta content=\"New analyses from the Phase 3 monarchE trial of two years of Verzenio treatment in node-positive, high risk early breast cancer show similar efficacy across age groups and in patients who had dose...\" property=\"og:description\"/>"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "keywords = soup.find(\"meta\", attrs={'property':'og:description'})\n",
    "keywords"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "c0701042",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.8"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
